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ABSTRACT 
 
Orthosiphon stamineus Benth and Morinda citrifolia L. are considered an important 
traditional folk medicine and commonly used in Malaysia for treating many diseases. In 
this study, the ethanol extracts of O. stamineus and M. citrifolia were evaluated for their 
hepatoprotective and antioxidant activities; in vivo against thioacetamide-induced liver 
cirrhosis in rats and in vitro against H2O2-induced hepatotoxicity in WRL-68 liver cell 
line, as well as to investigate their immunomodulatory and antibacterial effects.  
Orthosiphon stamineus and Morinda citrifolia were evaluated for their antioxidant 
activities using DPPH, ABTS and FRAP. In addition the phenolic and flavonoids 
contents were determined. Seven groups of adult SD rats were used in the 
hepatoprotective experiment. Group 1 as normal control group, while groups 2 to 7 
were injected intraperitoneally with 200 mg/kg of thioacetamide (TAA) thrice weekly 
for two months and orally administered respectively with 10 % Tween 20, 50 mg/kg 
silymarin, 200 mg/kg and 100 mg/kg ethanol extract of O. stamineus and M. citrifolia 
daily for two months. The hepatoprotective activity was evaluated using the following 
parameters; body and liver weight, serum liver biochemical markers, liver gross 
morphology and histopathology, as well as endogenous antioxidant markers. 
Furthermore, the liver fibrosis related genes namely; TGFβ1, MMP2, TIMP1 and Coll α 
were estimated for the change in gene expression levels using RT-PCR. In addition, the 
ethanol crude extracts of O. stamineus and M. citrifolia and their isolated fractions were 
investigated against H2O2-induced hepatotoxicity in WRL-68 liver cell line and the 
percentage of cell viability using MTT assay and the antioxidant level markers were 
assessed. The immunomodulatory potential of the extracts were investigated by MTT 
assay against human peripheral blood mononuclear cells (PBMCs), while the 
antibacterial activity was investigated by disc diffusion and determination of minimum 
iii 
 
inhibitory concentration (MIC) against four Gram-positive and Gram-negative bacterial 
strains. Finally, LC-MS was used for identification of the active constituents of the 
fractions that proved to have hepatoprotective activity. 
Orthosiphon stamineus exhibited significant free radical scavenging activity with DPPH 
(IC50 21.4 µg/ml), at the same time, showed high total phenolic and flavonoidal 
contents. In animal experiments, the hepatotoxic group showed a coarse granulation on 
the liver surface when compared to the smooth aspect observed on the liver surface of 
normal and treatment groups. Histopathological study confirmed the result. Moreover, 
there was a significant (P < 0.05) increase in serum liver biochemical parameters (ALT, 
AST, ALP and bilirubin) and the level of liver lipid peroxidation index 
malondialdehyde (MDA), accompanied by a significant decrease in the level of total 
protein, albumin, catalase, superoxide dismutase and glutathione peroxidase in the TAA 
control group comparing with normal group. The 200 mg/kg treatment groups of both 
plants significantly restored the elevated liver function enzymes and antioxidant 
parameters near to normal and significantly down-regulated the expression of the liver 
fibrosis genes. The oxidative stress by H2O2 resulted in a decrease of cell viability to 
41.9 %, while pre-treatment with crude extracts of O. stamineus and M. citrifolia, as 
well as with fraction 3 of O. stamineus and fraction 2 of M. citrifolia were found 
significantly (P < 0.01) increase the cell viability to 81.1 %, 76.4 %, 95.1 % and 86.1 % 
respectively at concentration 100 µg/ml. The hepatoprotective and antioxidant activity 
could be claimed to the following flavonoids; ponkanetin, eupatorin, TMF and 
salvigenin that were identified in O. stamineus F3 and scopoletin and P- coumaric acid, 
which were identified in M. citrifolia F2. In conclusion, this study showed that O. 
stamineus and M. citrifolia exhibit potent antioxidant properties, immunomodulatory 
activity and could be an effective herbal and efficient remedy for chemical-induced 
hepatic cirrhosis, thus may be a highly promising candidate drugs.  
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ABSTRAK 
Orthosiphon stamineus dan Morinda citrifolia dikenali sebagai ubatan tradisional yang 
penting dan kerap digunakan untuk mengubati pelbagai penyakit di Malaysia. Bagi 
kajian ini, ekstrak etanol O. stamineus dan M. citrifolia diuji untuk menilai aktiviti 
pelindung hati dan antioksidan masing-masing; secara in vivo di dalam tikus yang 
mengalami sirosis hati akibat thioacetamide dan secara in vitro di dalam sel-sel hati 
WRL-68 yang mengalami ketoksikan akibat H2O2, serta menyiasat kesan modulasi 
sistem imun dan antimikrobial.  
O. stamineus dan M. citrifolia dinilai untuk aktiviti antioksidan dengan menggunakan 
DPPH, ABTS, FRAP, jumlah fenol dan asai kandungan flavanoid. Tujuh kumpulan 
tikus SD dewasa digunakan untuk eksperimen melindungi hati. Kumpulan 1 adalah 
kumpulan kawalan normal, manakala kumpulan-kumpulan 2 ke 7 disuntik secara 
intraperitoneal dengan 200 mg/kg thioacetamide (TAA) tiga kali seminggu selama dua 
bulan dan diberi 10 % Tween 20, 50 mg/kg silymarin, 200 mg/kg atau 100 mg/kg 
ekstrak etanol O. stamineus and M. citrifolia secara oral selama dua bulan. Aktiviti 
perlindungan hati dinilai melalui parameter-parameter berikut; berat badan dan hati, 
petanda biokimia hati di dalam serum, morfologi nyata dan histopatologi hati serta 
petanda antioksidan tisu hati. Di samping itu, gen yang berkait dengan fibrosis hati, 
yakni; TGFβ1, MMP2, TIMP1 dan Coll α diuji secara RT-PCR untuk mengesan 
perubahan di dalam ekspresi gen. Ekstrak etanol kasar daripada O. stamineus dan M. 
citrifolia serta pecahan kromatografi masing-masing pula diperiksa secara in vitro di 
dalam sel hati WRL-68 yang mengalami ketoksikan akibat H2O2 dan penilaian 
peratusan viabiliti sel menggunakan asai MTT dan petanda paras antioksidan. Potensi 
untuk memodulasi sistem imun oleh ekstrak-ekstrak ini dikaji melalui asai MTT ke atas 
sel-sel mononuklear darah periferi manusia (PBMC). Keberkesanan antibakteria dikaji 
dengan menggunakan cakera sebar dan kepekatan minimum untuk mencapai perencatan 
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(MIC) ke atas empat jenis bakteria Gram-positif dan Gram-negatif. LC-MS digunakan 
untuk mengenal-pasti juzuk aktif yang terbukti mempunyai aktiviti yang mampu 
melindungi hati.  
O. stamineus menampakkan aktiviti memerangkap radikal bebas yang signifikan  
dengan DPPH IC50 21.4 µg/ml, dan juga menunjukkan kandungan jumlah fenol dan 
flavanoid yang tinggi. Eksperimen tikus menunjukkan kumpulan ketoksikan hati 
mempunyai granulasi kasar di permukaan hati berbanding dengan permukaan licin yang 
dilihat pada hati-hati daripada kumpulan normal dan kumpulan yang dirawat. Kajian 
histopatologi mengesahkan keputusan ini; di samping itu terdapat penambahan 
signifikan (P < 0.05) bagi parameter biokimia hati di dalam serum (ALT, AST, ALP 
dan Bilirubin) dan paras indeks malondialdehyde (MDA) bagi pengoksidan lipid hati, 
berserta pengurangan signifikan paras jumlah protein, Albumin, 
katalase, superoxide dismutase danglutathione peroksida bagi kumpulan kawalan TAA 
berbanding kumpulan normal. Kumpulan-kumpulan yang dirawat dengan dos 200 
mg/kg memulihkan paras tinggi enzim fungsi hati dan parameter antioksidan hampir ke 
paras normal dan menurunkan dengan signifikan regulasi ekspresi gen fibrosis hati. 
Tekanan oksidatif H2O2 daripada mengakibatkan viabiliti sel merosot ke 41.9 %, 
manakala prarawatan dengan ekstrak O. stamineus, M. citrifolia, pecahan 3 O. 
stamineus dan pecahan 2 M. citrifolia berkepekatan 100 100 µg/ml menyebabkan 
penambahan signifikan (P < 0.01) bagi viabiliti sel ke 81.1 %, 76.4 %, 95.1 % dan 86.1 
%. Kesimpulan kajian ini ialah O. stamineus dan M. citrifolia mempunyai kesan 
antioksidan yang kuat, aktiviti modulasi sistem imun dan berkesan sebagai rawatan 
herba yang efisien untuk sirosis hati yang diakibatkan oleh bahan kimia, dan 
mempunyai potensi yang tinggi untuk dijadikan ubat.   
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CHAPTER I 
INTRODUCTION  
 
1.1 Introduction 
The liver is the largest internal organ in the body with four lobes of different size and 
shape and surrounded by a firm layer of connective tissue called Glisson’s capsule 
encloses the whole liver. It gets the nutrients and oxygen through the main hepatic 
blood vessels; portal vein and hepatic artery. The lobes of liver are made up of many 
functional units called lobules. Lobules are the functional units of the liver; each lobule 
is made up of either parenchymal cells (hepatocytes), which are the basic metabolic 
cells, or non-parenchymal cells [hepatic stellate cells (HSC), kupffer cells and 
sinusoidal endothelial cells] (Gressner, 1991).   
Liver has a pivotal role in regulation of physiological processes. It is responsible for the 
synthesis of blood clotting factors, bile secretion, metabolism of lipid, carbohydrate and 
proteins, elimination of many substances, blood detoxifications, synthesizes, and 
regulation of essential hormones (Heidelbaugh & Bruderly, 2006). Furthermore, 
detoxification of several drugs and xenobiotics takes place in liver. Liver diseases have 
become a worldwide problem and are associated with significant morbidity and 
mortality. The principal causative factors for the liver diseases in developed countries 
are excessive alcohol consumption, and viral-induced chronic liver diseases while in the 
developing countries the most frequent causes are environmental toxins, parasitic 
disease, hepatitis B and C viruses, and hepatotoxic drugs (certain antibiotics, 
chemotherapeutic agents, high doses of paracetamol, thioacetamide (TAA), carbon 
2 
 
tetrachloride (CCl4), etc) (Schuppan & Afdhal, 2008). Ninety percent of cases with 
hepatocellular carcinoma are associated with liver cirrhosis (Okazaki et al., 2001).  
Liver cirrhosis was introduced for the first time in 1819 by Laennec (Roguin, 2006). It 
is derived from the Greek word scirrhus and is used to describe the yellowish of the 
liver seen at autopsy. The fatal and irreversible cirrhosis is the end-stage of most liver 
pathologies of different etiologies and leads to metabolic alterations and chronic liver 
dysfunction. The high prevalence of these liver disorders worldwide places them among 
the most serious diseases. Moreover, the cost of cirrhosis on economy such as hospital 
costs, lost productivity and human suffering is very high. Chronic liver cirrhosis and 
drug induced liver injury accounting the ninth leading cause of death by disease in 
western and developing countries (Saleem et al., 2010) . Liver cirrhosis is a disease of 
liver caused due to the change in structure and function of liver. Liver in patients with 
cirrhosis characterized by replacement of normal tissue with scar and unhealthy tissue, 
blocking the blood flow through the organ which in turn leads to accumulation of toxins 
in the body. These toxins further give rise to other complications, so it is a critical stage 
of chronic liver diseases that can produce liver failure accompanied with portal 
hypertension, bleeding tendency, an impaired metabolic function, hepatic 
encephalopathy and hepatocarcinoma. Liver cirrhosis developing in response to chronic 
hepatocellular damage characterized by particular cellular reactions that are controlled 
by a several cytokines and lead finally to the excessive deposition of extracellular 
matrix proteins (Li & Friedman, 1999). As these processes continue, the liver 
architecture is change resulting in severe physiological and pathology consequences. 
Histologically cirrhosis is defined as a widespread hepatic process characterized by the 
conversion of normal liver architecture into abnormal nodules and fibrosis. An 
appropriate degenerative development of the sclerosis connective tissue in some 
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patients, finally leads to cirrhosis, which is the common endpoint of a variety of chronic 
liver diseases (Poli, 2000). 
Oxidative stress plays a key role in cell injury and necrosis induced during liver 
cirrhosis. To date the pathogenesis of liver fibrosis is not completely clear, but there is 
no doubt that free radicals including reactive oxygen species (ROS) play an important 
role in liver pathological changes, particularly in cases of toxic liver diseases and 
alcoholic intoxication (Poli & Parola, 1997). The free radicals such as ROS, including 
hydroxyl radicals, superoxide anions, and hydrogen peroxide, play a remarkable role in 
promoting tissue damage in living organisms. They may lead to cell damage through 
membrane lipid peroxidation and DNA mutations and as a consequence of that many 
diseases such as cancer may develop. Lipid peroxidation of unsaturated fatty acids in 
cell membranes leads to a decrease of membrane fluidity and to a disruption of 
membrane integrity and function, which is implicated in serious pathological changes 
(Halliwell, 1987). It is well known that oxidative stress involved in the pathogenesis of 
hepatic cirrhosis. Consequently, the oxidative stress and free radicals were considered 
as primary causes of the liver fibrosis. Most of the hepatotoxic chemicals damage liver 
cells mainly by inducing lipid peroxidation and other oxidative damages in liver. 
Enhanced lipid peroxidation produced during the liver microsomal metabolism of 
ethanol may result in hepatitis and cirrhosis. The protective mechanisms of dietary 
antioxidants may be of a great importance. Therefore, many natural and artificial agents 
possessing antioxidant properties have been proposed to prevent and treat hepatopathies 
induced by oxidative stress (Lieber, 1996). 
Although fibrosis and cirrhosis are of high incidence worldwide, therapeutic 
management of these diseases is still insufficiently, as most of them focus mainly on 
symptoms rather than on blocking fibrosis mechanisms itself (Franklin, 1995). Despite 
of the tremendous advances made, there is no effective and safe medicine for hepatic 
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cirrhosis; consequently control of liver diseases has become a major goal of modern 
medicine. Till date, there is only few numbers of drugs available for the treatment of 
liver diseases (Chatterjee, 2000).  Therefore, different medicinal plant extracts are tested 
for their potential as antioxidant and hepatoprotective liver injury in experimental 
animal model. 
Long time ago, human started using herbal plants in the treatment of various diseases. 
Herbal drugs have gained popularity and importance in recent years because of their 
efficacy, safety, and cost effectiveness. Medicinal plants are widely used all over the 
world as folk medicine for several purposes. They have been used as antibacterial, 
antioxidant, antiulcer, anti-inflammatory, antiviral and anticancer agents especially in 
developing countries where infectious diseases are endemic and health services and 
hygiene facilities are inadequate. Estimations made by the World Health Organization 
(WHO) revealed that 80 % of people who live in developed countries generally use 
traditional medicine (Rahim & Khan, 2006). One of the most important and well-
documented use of medicinal plants traditionally is their use as hepatoprotective drugs. 
Hence, there is an ever increasing need for safe hepatoprotective drugs (Agarwal, 2001). 
In the absence of reliable hepatoprotective drugs in modern medicine, a large number of 
herbal preparations have become increasingly popular for the treatment of liver 
disorders (Chatterjee, 2000). A number of herbals show promising activity, including 
silymarin for liver cirrhosis, Phyllantus amarus in chronic hepatitis B, glycyrrhizin to 
treat chronic viral hepatitis, and some herbal combinations from China and Japan that 
have been scientifically proven for treatment of liver diseases (Stickel & Schuppan, 
2007). Silymarin, a flavonolignan from “milk thistle” Silybum marianum, is widely 
used for hepatoprotection. Silymarin showed good protection in different toxic models 
of induced liver cirrhosis experiments by using laboratory animals (Ghosh et al., 2010). 
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Liver cell injury caused by various toxicants such as certain chemotherapeutic agents, 
thioacetamide, CCl4, etc., long term alcohol consumption and some viruses is well-
studied. Enhanced lipid peroxidation during metabolism of ethanol may result in 
development of hepatitis leading to cirrhosis. Thioacetamide (TAA) induced 
hepatotoxicity is an experimental model world widely used for the study of 
hepatoprotective effects of plant extracts and other kind of drugs. The experimental 
induction of liver cirrhosis by long exposure of TAA results in histological and 
biochemical changes resembles human liver cirrhosis (Zimmermann et al., 1987). The 
TAA model is more reliable and easy for induced liver cirrhosis than the CCl4 model 
(Kreft et al., 1999).  
Nowadays there is growing focus to evaluate scientific basis for the use of traditional 
herbal medicines which are claimed to possess hepatoprotective and antioxidant 
activity. As shown by recent in vivo and in vitro studies, plant antioxidants, particularly 
flavonoids and other phenolics, show a magnificent potency to prevent liver cirrhosis of 
different etiology (Gebhardt, 2002). Since only few number of herbs have been studied 
so far have just opened a wide horizon, it is worth to screen other plant extracts and 
natural compounds in appropriate model systems and to identify further compounds 
combining antioxidant properties with other effectors functions. Such studies may lead 
to new drugs particularly appropriate and specifically designed to block liver cirrhosis at 
early steps of disease. This study was carried out to assess the in vivo hepatoprotective 
and antioxidant activities of Orthosiphon stamineus Benth and Morinda citrifolia L. 
against thioacetamide-induced hepatotoxicity in rats to prove scientifically the 
traditional use of both plants against liver disorders as well as, to determine their in 
vitro antioxidant, immunomodulatory and antibacterial properties of both plants.  
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1.2 Objectives 
1.2.1 General 
To investigate the in vivo and in vitro hepatoprotective, antioxidant, immunomodulatory 
and antibacterial activities of the crude extracts of O. stamineus and M. citrifolia, as 
well as to identify the active constituents of both medicinal plants.   
 
1.2.2 Specific 
1) To assess the hepatoprotective activity of O. stamineus and M. citrifolia ethanol 
crude extracts against thioacetamide-induced liver cirrhosis in rats (in vivo) and 
against H2O2-induced hepatotoxicity in WRL-68 normal liver cell line (in vitro).   
2) To determine the antioxidant properties of the ethanol crude extracts of these 
two plants (in vitro) and in rats liver homogenate (in vivo).  
3) To evaluate the changes in gene expression levels between normal, control and 
treatment animal groups. 
4) To evaluate the immunomodulatory activities of the ethanol extracts of both 
plants against human peripheral blood mononuclear cells (PBMCs).  
5) To fractionate and identify the active constituents of the plant extracts with 
hepatoprotective activity. 
6) To assess the in vitro antibacterial activities of both plant extracts. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Liver cirrhosis 
Liver is a vital organ play a major role in metabolism and excretion of drugs and 
xenobiotics from the body. Liver injury or liver dysfunction is a major health problem 
that challenges not only health care professionals but also the pharmaceutical industry 
and drug regulatory agencies (Heidelbaugh & Bruderly, 2006). 
Cirrhosis is a complication of many liver diseases that is characterized by abnormal 
structure and function of the liver. The diseases that lead to cirrhosis do so because they 
injure and kill liver cells and the inflammation and repair that is associated with the 
dying liver cells causes scar tissue to form. The liver cells that do not die multiply in an 
attempt to replace the cells that have died. This results in clusters of newly-formed liver 
cells (regenerative nodules) within the scar tissue. Septa are connective tissue 
membranes of various widths. They result from either collapse of pre-existing 
parenchyma or formation of new connective tissue fibres. Septa are wide when they 
form after extensive collapse of lobular or nodular parenchyma. They cause functional 
manifestations when they connect central with portal canals and contain vessels 
permitting short circuits of blood flow. Cirrhosis is characterized conventionally by 
progressive hepatocytes injury and a nodular parenchyma followed by regeneration and 
widespread fibrosis, with hepatocellular necrosis leading to disorganization of lobular 
architecture (Schuppan & Afdhal, 2008).  
Cirrhosis is better described as the result of abnormal reconstruction of the pre-existing 
lobular architecture. The first problem in cirrhosis, the relationship between blood and 
liver cells is destroyed. Even though the liver cells that survive or are newly-formed 
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may be able to produce and remove substances from the blood, they do not have the 
normal, intimate relationship with the blood, and this interferes with the liver cells' 
ability to add or remove substances from the blood. In addition, the scarring within the 
cirrhotic liver obstructs the flow of blood through the liver and to the liver cells. 
Because of the obstruction to flow and high pressures in the portal vein, blood in the 
portal vein seeks other veins in which to return to the heart, veins with lower pressures 
that bypass the liver. Unfortunately, the liver is unable to add or remove substances 
from blood that bypasses it. It is a combination of reduced numbers of liver cells, loss of 
the normal contact between blood passing through the liver and the liver cells, and 
blood bypassing the liver that leads to many of the manifestations of cirrhosis. A second 
reason for the problems caused by cirrhosis is the disturbed relationship between the 
liver cells and the channels through which bile flows. Bile is a fluid produced by liver 
cells that has two important functions: to aid in digestion and to remove and eliminate 
toxic substances from the body. The bile that is produced by liver cells is secreted into 
very tiny channels that run between the liver cells that line the sinusoids, called 
canaliculi. The canaliculi empty into small ducts which then join together to form larger 
and larger ducts. Ultimately, all of the ducts combine into one duct that enters the small 
intestine. In this way, bile gets to the intestine where it can help with the digestion of 
food. At the same time, toxic substances contained in the bile enter the intestine and 
then are eliminated in the stool. In cirrhosis, the canaliculi are abnormal and the 
relationship between liver cells and canaliculi is destroyed, just like the relationship 
between the liver cells and blood in the sinusoids. As a result, the liver is not able to 
eliminate toxic substances normally, and they can accumulate in the body. To a minor 
extent, digestion in the intestine also is reduced (Schuppan & Afdhal, 2008).  
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2.1.1 Causes of liver cirrhosis 
Liver cirrhosis is among the most serious diseases. It may be developed as a 
consequence of chronic viral hepatitis B and/or C, excessive alcohol consumption, 
biliary obstruction, non-alcoholic fatty liver disease, autoimmune liver diseases, 
hemochromatosis, alpha-1 antitrypsin deficiency, Wilson’s disease, and liver cell injury 
due to toxic chemicals such as certain antibiotics, chemotherapeutic agents, aflatoxin, 
thioacetamide, carbon-tetrachloride, chlorinated hydrocarbons, etc.) (Heidelbaugh & 
Bruderly, 2006). Although less likely, other causes of cirrhosis include parasitic 
infections and prolonged exposure to environmental toxins. Sometimes more than one 
cause is present in the same patient. In the western world, chronic alcoholism and 
hepatitis C are the most common causes. Numerous clinical studies have demonstrated 
that the patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection 
may progress to liver cirrhosis. More than 60-70 % of individuals infected with HCV 
develop chronic liver disease with intermittent necrosis and fibrosis. A significant 
number of patients with HCV chronic hepatitis progress to cirrhosis and even to 
hepatocellular carcinoma (Davis et al., 1994; Poynard et al., 1997). It has been 
estimated that approximately 14 - 16 millions of people are infected with this virus in 
South East Asia region and about 6 % of the total population in that region are carriers 
of this virus. A vaccine has become available for immunization against hepatitis B 
virus. Hepatitis C and hepatitis E infections are also common in countries of South East 
Asia region. However, some liver cirrhosis occurs in patients without evidence of 
hepatotropic viral infection. Tobacco smoking with alcohol consumption according to 
(Corrao et al., 1994) plays a role in causing liver cirrhosis. Little is known on 
modulators of cirrhosis risk, apart from other diseases that cause liver injury (such as 
the combination of alcoholic liver disease and chronic viral hepatitis, which may act 
synergistically in leading to cirrhosis). Alcoholic cirrhosis has a worse prognosis than 
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primary biliary cirrhosis and cirrhosis due to hepatitis. The risk of death due to all 
causes is increased twelvefold; if one excludes the direct consequences of the liver 
disease, there is still a fivefold increased risk of death in all disease categories (Sorensen 
et al., 2003).  
 
 2.1.2 Pathology 
Hepatic fibrosis is a wound healing process and the pathology of liver cirrhosis is 
characterized by the abnormal and progressive deposition of large amount of 
extracellular matrix (ECM) proteins in response to liver injury (Stalnikowitz & 
Weissbrod, 2003). Liver cirrhosis has been believed to be an irreversible disease which 
causes serious complications. Cirrhosis is defined as diffuse involvement of the whole 
liver with slowly progressive necrosis of liver cells (hepatocytes) leading to liver 
failure. Pathogenesis of cirrhosis is complex. The liver cells are injured by a chronic 
disease process, which then undergo inflammatory changes leading to cell death 
(necrosis) and fibrosis. Fibrosis is initiated by activation of stellate cells, which are 
induced by cytokines, active oxygen intermediates, autocrine signals and paracrine 
signals implemented by hepatocytes and Kupffer cells. Stellate cells initiate fibrosis by 
swelling, loosing retinoids and up regulating receptors for proliferative cytokines 
transforming growth factor β1 (TGF-β1) and platelet-derived growth factor 
(PDGF). Stellate cell activation in chronic liver disease also leads to expression of α-
actin, which is a contractile protein. The contractions are induced by endothelin, 
nitrousoxide and prostaglandins. Normal matrix in spaces of disse in the liver are 
replaced by collagen 1, 3 and fibronectin. Sub-endothelial fibrosis leads to the loss of 
endothelial fenestrations resulting in the impairment of liver functions. Tissue inhibitors 
of metaloproteinases (TIMPs) increase and inhibit matrix metaloproteinases (MMPs) 
(degrade excessive matrix collagen). The deposition of collagen and its maturation is 
11 
 
enhanced around surfaces with reduced fluid exchange like basement membranes, 
damaged hepatocytes, and loaded macrophages, as well as by reduced oxygen tension 
(Popper, 1977). Hepatic stellate cells, which reside in the space of disse in close contact 
with both sinusoidal endothelial cells and hepatocytes, play multiple roles in the 
pathophysiology of the liver. When liver injury occurs, they undergo transformation 
into myofibroblasts that actively proliferate in response to PDGF, produce increased 
amount of ECM material, show augmented contractility accompanied by the expression 
of smooth muscle α-actin, secrete TGF-β and monocyte chemotactic protein-1 (MCP-1), 
lose the retinoid, and exhibit active apoptosis (Friedman, 1997). Liver injury is 
associated with activation of hepatic stellate cells. Upon liver injury (Figure 2.1), 
changes occur in the subendothelial space of disse and sinusoid such as alterations in 
both cellular responses and ECM composition. This contributes to the loss of hepatocyte 
microvilli and sinusoidal endothelial fenestrae, which result in deterioration of hepatic 
function. Kuppfer cell (macrophage) activation accompanies liver injury and contributes 
to paracrine activation of stellate cells. HSCs major phenotypic changes after activation 
include proliferation, contractility, fibrogenesis (synthesis of fibrotic matrix rich in 
collagen I), matrix degradation, chemotaxis, retinoid loss, and white blood cell 
chemoattraction. The ECM components in fibrotic liver are similar regardless of the 
underlying cause (Safadi & Friedman, 2002). The pathological changes seen in cirrhosis 
are important in the diagnosis of the disease as well as for etiological diagnosis. They 
include fibrosis involving both central veins and peripheral areas, formation of 
regenerative nodules due to the hyperplasia of surviving liver cells and distortion of 
normal architecture of the liver. Macroscopically, the liver is initially enlarged, but with 
progression of the disease, it becomes smaller. Its surface is irregular, the consistency is 
firm and the colour is often yellow. Depending on the size of the nodules there are three 
macroscopic types: micronodular, macronodular and mixed cirrhosis. In micronodular 
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form (portal cirrhosis) regenerating nodules are less than 3 mm of uniform size. In 
macronodular cirrhosis (post-necrotic cirrhosis), the nodules are larger than 3 mm. The 
mixed cirrhosis consists in a variety of nodules with different sizes. Microscopically the 
nodules are composed of hyperplastic hepatocytes separated by fibrous connective 
tissue. Excess hepatic connective tissue results from collapse (passive septa) or from 
formation of new fibres (active septa). Collapse induces additional fibre formation. 
Connective tissue consists of a matrix of glycoproteins and proteoglyeans, many 
sulfated, and scleroproteins of which collagen is the most important in the liver. The 
liver cells are enlarged and the vasculature distorted due to the fibrosis involving portal 
triads. Fistulous communications may be formed between portal veins and hepatic 
arterioles. The fibrosis in cirrhosis can lead to destruction of other normal tissues in the 
liver: including the sinusoids, the space of disse, and other vascular structures, which 
leads to altered resistance to blood flow in the liver and portal hypertension 
(Heidelbaugh & Bruderly, 2006).  
 
Figure 2.1 Diagram illustrates the four major liver cell types (hepatocytes, Kupffer cells, 
endothelial cells and stellate cells) in healthy and injured liver. (Adapted from (Asselah 
et al., 2009)). 
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2.1.3 Immunology (molecular and cellular aspects of liver cirrhosis) 
Complex cellular and molecular mechanisms resulting from chronic activation of tissue 
repair mechanism following liver tissue injury have been characterized. Liver damage is 
always associated with cellular necrosis, increase lipid peroxidation and depletion in the 
tissue glutathione levels. In addition serum level of many biochemical markers like 
AST, ALT, Alkaline phosphatase and bilirubin are elevated. Thus, cirrhosis is a 
consequence of chronic liver disease characterized by replacement of liver tissue by scar 
tissue, fibrosis, regenerative nodules, and blocking the portal flow of blood through the 
organ leading to loss of liver function. Hepatic fibrosis, or the deposition of ECM, is 
associated with inflammation and cell death, which accompanies the repair processes, 
and is a consequence of severe liver damage that occurs in many patients with chronic 
liver injury of any etiology (Re et al., 1999). Many forms of liver injury are marked by 
fibrosis. Fibrosis is defined as an excess deposition of the components of ECM (i.e., 
collagens, glycoproteins, and proteoglycans) within the liver. This response to liver 
injury potentially is reversible. In contrast, in most patients, cirrhosis is not a reversible 
process. The fibrotic process recognises the involvement of various cells and different 
factors in bringing about an excessive fibrogenesis with disruption of intercellular 
contacts and interactions of extracellular matrix composition. However, Kupffer cells, 
together with recruited mononuclear cells, and hepatic stellate cells are by far the key-
players in liver fibrosis. Their cross-talk is triggered and favoured by a series of 
chemical mediators, with a prominent role played by the TGF-β (Poli, 2000). In liver, 
the inflammation process gives rise to different pathways of lymphocyte recruitment 
and migration, probably directly related to type of insult. These pathways involve portal 
tract, sinusoid and hepatic vein. Composition and distribution of the inflammatory 
infiltrate may include T lymphocytes (more peripheral) B lymphocytes (mainly central), 
plasma cells, histiocytes (granuloma), eosinophils, neutrophils, natural killer (NK) cells, 
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and mast cells, which in turn give rise to secondary changes such as phenotypic 
differences among different vascular compartments (Guti rre -Ru    et al., 2002). 
Leukocytes that are recruited to the liver during injury join with Kupffer cells in 
producing compounds that modulate stellate cell behavior. Monocytes and macrophages 
are involved in inflammatory actions by producing large amounts of nitric oxide (NO) 
and inflammatory cytokines such as tumor necrosis factor-α (TNF-α) which have a 
direct stimulatory effect on stellate cell collagen synthesis. In recent years, a significant 
role for pro-inflammatory cytokines such as TNF-α, in the onset of liver disease, has 
been indicated both by clinical observations of an enhanced circulating level of TNF-α 
and other cytokines in patients and by results of studies with animal models. Kupffer 
cells respond to the endotoxin challenge by producing a battery of cytokines and 
chemokines, including TNF-α, interleukin (IL)-1β , IL-6, and prostaglandin E2 
(McClain et al., 1999; Thurman et al., 1999). The influx of Kupffer cells coincides with 
the appearance of stellate cell activation markers. Kupffer cells can stimulate matrix 
synthesis, cell proliferation, and release of retinoids by stellate cells through the actions 
of cytokines especially TGF-β1 and reactive oxygen intermediates/lipid peroxides. 
Kupffer Cells, the resident macrophages in the sinusoids of the liver, have been widely 
implicated in hepatic injury such as endotoxin–mediated live injury.  
In the injured liver, HSCs are regarded as the primary target cells for inflammatory and 
per-oxidative stimuli, and are transformed into myofibroblast-like cells. These HSCs are 
referred to as activated cells, and this activation is accompanied by a loss of cellular 
retinoid, and the synthesis of α-smooth muscle actin (α-SMA) and large quantities of the 
major components of the ECM, including collagen types I, III, and IV, fibronectin, and 
laminin (Cassiman et al., 2001). During active hepatofibrogenesis, however, HSCs 
become the major ECM producing cell type, with a predominant production of collagen 
type l. Activation of HSC is regulated by several soluble factors, including cytokines 
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such as TGF-β1, chemokines, growth factors, and products of oxidative stress as well as 
by extensive changes in composition and organization of extracellular matrix 
components. There is evidence to show that the products of lipid peroxidation modulate 
collagen gene expression in HSC (Bedossa et al., 1994). Of all the cytokines and growth 
factors produced TGF–β and IL- 6 are two main fibrogenic cytokines. While HSC 
activation is taking place in liver and cytokines and signal transduction pathways are 
being stimulated, TGF–β1 plays a central role in fibrosis, contributing to influx and 
activation of inflammatory cells as well as activation of HSC. TGF-β is produced by 
Kupffer cells and HSC, it up-regulates the transcription of collagen I genes and induces 
the expression of TIMP-1, a tissue inhibitor of MMPs involved in collagen degradation. 
Four members of the family of the TIMPs have been so far described (Arthur, 1998). 
Interestingly they are able to inhibit all MMPs. IL- 6 which is produced by HSC from 
normal or cirrhotic livers, it up- regulates the expression of TGF-β in HSC from 
cirrhotic livers. Previous study indicates that reactive oxygen intermediates in general, 
and H2O2 in particular, are important mediators of TGF-β actions in HSC (Friedman, 
1997). Following cell activation in vivo, HSCs express the genes encoding the key 
components required for matrix degradation such as MMP-l and -2. In normal liver, 
matrix protein degradation is accomplished by a family of enzymes called MMPs. To 
date, four subclasses of MMPs have been defined on the basis of relative substrate 
specificity. Stellate cells and Kupffer cells are certainly recognized as source of MMPs 
(Benyon & Arthur, 2001). However, through the activation of tissue inhibitor of TIMP-l 
and -2, activated HSCs also inhibit the activity of interstitial collagenases, which 
degrade fibrillar collagen. Most of the hepatocellular injury inducer and subsequently 
hepatic inflammation, finally resulting in HSC activation and collagen deposition 
(Bataller & Brenner, 2001). Although hepatocytes are the major site for oxygen 
utilization, non-parenchymal cells also are sources of ROS, and may thereby contribute 
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to hepatocyte necrosis and/or HSC activation. Kupffer cells are activated by a variety of 
stimuli to produce ROS. ROS include hydrogen peroxide (H2O2), hydroxyl (OH), 
superoxide (O2) and nitric oxide (NO) free radicals, highly heterogeneous in terms of 
reactivity against cellular targets. Inflammatory cells, such as Kupffer cells and 
invading mononuclear cells, which release cytokines, TGF-β l and PDGF may also 
contribute to the fibrogenic response to liver injury (Figure 2.2). Furthermore, TGF- β l 
is a key fibrogenic mediator that can enhance ECM deposition and inhibit MMP activity 
(Casini et al., 1993). It is also noteworthy that TGF- β is an inhibitor of the proliferation 
of hepatocytes, and that, at higher concentrations, TGF- β induces oxidative stress 
leading to hepatocyte apoptosis. After that, the fibrous tissue (septa) separate hepatocyte 
nodules, which eventually replace the entire liver architecture, leading to decreased 
blood flow throughout.  
There is extensive evidence of altered immune reactivity in some types of liver disease. 
Mitochondrial antibody, smooth muscle antibody, and antinuclear factors have been 
demonstrated in primary biliary cirrhosis and chronic active hepatitis but the pathogenic 
significance of these auto-antibodies is uncertain. The histology of these diseases shows 
infiltration with small lymphocytes but specific cell-mediated immune reactivity has 
been little studied so far (Flier et al., 1993). 
 
17 
 
 
Figure 2.2 Diagram illustrates liver injury-mediated hepatofibrogenesis. MDA: 
malondialdehyde; HNE: 4-hydroxynonenal; TGF: transforming growth factor; PDGF: 
platelet-derived growth factor. [Adapted from (Re et al., 1999)]. 
 
2.1.4 Symptoms and complication 
In most cases with liver cirrhosis have no symptoms in the early stages of the disease. 
However, as scar tissue replaces healthy cells, liver function starts to fail and a person 
may experience the following symptoms (Schuppan & Afdhal, 2008): 
• Jaundice (Yellowing of the skin and eyes) 
•  Fatigue and weakness 
•  Itching  
•  Loss of appetite and nausea 
•  Easy bruising from decreased production of blood clotting factors. 
• Weight loss 
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• Nail changes such as Muehrcke's lines and Terry's nails (proximal two-thirds of 
the nail plate appears white with distal one-third red) due to hypo-albuminemia. 
• Hepatomegaly and splenomegaly (increase in size). 
• Musty odor in breath as a result of increased dimethyl sulfide. 
As the disease progresses, the following complications may develop. In some people, 
these may be the first signs of the disease: 
•  Edema and ascites: When the liver loses its ability to make the protein albumin, 
water accumulates in the leg (edema) and abdomen (ascites).  
•  Spontaneous bacterial peritonitis  
• Esophageal variceal Bleeding  
•  Hepatic encephalopathy 
• Portal hypertension 
•  Hypersplenism  
•  Liver cancer (hepatocellular carcinoma) 
 
2.1.5 Diagnosis 
Liver cirrhosis may be diagnosed through more than one of the following methods 
(Schuppan & Afdhal, 2008): 
• Physical examination, patient history and symptoms. 
• Liver biopsy, which is the key for diagnosis.  
• Computerized tomography (CT or CAT) or magnetic resonance imaging (MRI) 
scans, and ultrasound examinations. 
• Laboratory finding: 
1. Abnormal elevation of bilirubin and other liver enzymes in blood (such as 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST)). 
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2. Slightly increase in alkaline phosphatase (ALP). 
3. Reduced level of albumin in blood. 
4. Prothrombin time (PT) increases, thrombocytopenia and reduced blood 
clotting factors. 
 
2.1.6 Prevention 
There are several ways to reduce the risk of developing liver cirrhosis (Flier et al., 
1993): 
 Stop abusing alcohol or limiting how much and how often of drink for those 
who do drink alcohol.  
 Avoiding high-risk sexual behaviour such as unprotected sexual contact with 
multiple partners. 
 Wearing protective clothing and a facemask for people who in contact with 
synthetic chemicals, such as cleaning products and pesticides.  
 Vaccination of susceptible patients against hepatitis B. 
 Eating a well-balanced, low-fat diet and taking vitamins. 
2.1.7 Treatment 
Treatment options for liver diseases such as cirrhosis, fatty liver, and chronic hepatitis 
are problematic. Although there is no cure for cirrhosis of the liver, but treatment can 
stop or delay further progression, minimize the damage to liver cells and reduce 
complications. The effectiveness of treatments such as interferon, colchicine, 
penicillamine, and corticosteroids are associated with the risk of relapse and the 
incidence of side-effects profound (Mavier & Mallat, 1995). So to date, no treatment 
has revealed efficient to prevent or to avoid the progress of this pathology and, in most 
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instances, patients receive treatment for the symptoms of cirrhosis (Mavier & Mallat, 
1995). Mostly the treatment aims the following:  
• Preventing further damage to the liver 
• Treating the complications of cirrhosis. 
•  Preventing liver cancer or detecting it early. 
When complications cannot be controlled or when the liver becomes so damaged from 
scarring that it completely stops functioning, a liver transplant is necessary. Physicians 
and patients are in need of effective therapeutic agents with low incidence of side-
effects.  
 
2.1.8 Liver cirrhosis and medicinal plants 
Medicinal plants have formed the basis for treatment of diseases in traditional medicine 
for thousands of years and continue to play a major role in the primary health. World 
Health Organization (WHO) reported that 80 % of the world population rely on the use 
of traditional medicine which is predominantly based on plant materials (WHO, 1993). 
According to Newman et al. (2003) all drugs approved by the US Food and Drug 
Administration (FDA), finding that 42 % of the 1031 drugs approved between 1981 and 
2002 are associated to natural products. The available synthetic drugs to treat liver 
disorders in this condition also cause further damage to the liver. Hence, herbal drugs 
have become increasingly popular and their use is wide-spread. The use of natural 
remedies for the treatment of liver diseases has a long history, starting with the 
Ayurvedic treatment, and extending to the Chinese, European and other systems of 
traditional medicines. The 21
st
 century has seen a paradigm shift towards therapeutic 
evaluation of herbal products in liver disease models by carefully synergizing the 
strengths of the traditional systems of medicine with that of the modern concept of 
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evidence-based medicinal evaluation, standardization and randomized placebo 
controlled clinical trials to support clinical efficacy (Thyagarajan et al., 2002). Different 
herbal plants as  natural sources have been evaluated for the treatment of hepatocellular 
damage in experimental animal models (Luper, 1998). In recent years many researchers 
have examined the effects of plants used traditionally by indigenous healers and 
herbalists to support liver function and treat diseases of the liver. In most cases, research 
has confirmed traditional experience and wisdom by discovering the mechanisms and 
modes of action of these plants as well as reaffirming the therapeutic effectiveness of 
certain plants or plant extracts in clinical studies. Several hundred plants have been 
examined for use in a wide variety of liver disorders. Just a handful has been fairly well 
researched. The latter category of plants include: Silybum marianum (milk thistle), 
Picrorhiza kurroa (kutkin), Curcuma longa (turmeric), Camellia sinensis (green tea), 
Chelidonium majus (greater celandine), Glycyrrhiza glabra (licorice), and Allium sativa 
(garlic) (Luper, 1999). The constituents of plant extracts have immune stimulating, liver 
protective and anti-inflammatory actions. The herbs stimulate hepatocytes production 
and for repairing and regeneration hepatocytes. Accumulative evidence for the 
effectiveness against fibrosis is now available for several plant-derived antioxidants. 
The most successful liver protective natural product is silymarin, a flavonolignan from 
the seeds of milk thistle Silibum marianum L. This extract is used exclusively for liver 
protection. Silymarin proved to be antifibrogenic in a rat fibrosis model (Jia et al., 
2001), where it led to a reduction of hepatic collagen accumulation by more than 35 %. 
It is well known that silymarin and its component silibinin have potent antioxidant 
activity (Pietrangelo et al., 1995). Medicinal plants are an important source of 
antioxidants (Rice-Evans, 2004). The secondary metabolites like phenolics and 
flavonoids from plants have been reported to be potent free radical scavengers. They are 
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found in all parts of plants such as leaves, fruits, seeds, roots and bark (Mathew & 
Abraham, 2006). 
2.2 Approaches to study hepatoprotective activity and screening models 
 Hepatoprotective agents are those compounds, which prevent the liver injury caused by 
hepatotoxic agents (Lee et al., 2000). There are several different approaches for the 
assessment of hepatoprotective activity such as the experimental animal (in vivo) or 
using in vitro model systems like rat isolated hepatocytes. Although the efficacy of 
hepatoprotective agents can best be demonstrated by in vivo studies, mechanistic details 
of this activity that can be derived from these studies, however, are sparse. Therefore, 
many in vitro studies with plant extracts, less complex fractions or isolated compounds 
give more information. 
 
2.2.1 In vivo models 
In vivo studies are the primary tools used to study liver damage and resolution of liver 
injury. For this purpose, animals are treated or pretreated with plant extracts, and liver 
injury is induced chemically. By induced hepatotoxicity using toxic chemical dose or 
repeated dose of hepatotoxin in rats and mice as they virtually mimic any form of 
naturally occurring liver disease. Hepatoprotective effects of herbal drugs and plant 
extraction are studied in vivo against chemicals (thioacetamide (TAA), Carbon 
tetrachloride (CCl4), alcohol, beta galactosamine,) and drugs (paracetamol, isoniazid, 
and rifampicin) (Sumanth, 2007). The hepatoprotective tested plant is usually 
administrated prior or along with the toxin, and if it’s effective it will prevent or reduce 
the liver injury. Morphological parameters such as liver volume, visible signs of 
necrosis and cirrhosis, biochemical parameters are evaluated to assess the damage. 
Among regular clinical analyses, the most useful are serum bilirubin, serum albumin, 
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serum alkaline phosphatase, serum ALT, AST, prothrombin time, gamma-glutamyl 
transpeptidase, and lactate dehydrogenase tests (Rahman et al., 2001; Schuppan et al., 
1999). 
Mode of hepatotoxicity of CCl4 is through membrane damage of hepatocyte, while TAA 
leads to centrilobular necrosis. The TAA model is easier to perform and more reliable in 
liver cirrhosis induction than the CCl4 models (Kreft et al., 1999). Since the TAA, CCl4 
and Paracetamol induced liver cirrhosis are the most widely used models, the 
mechanism of liver injury by these chemicals are explained below. 
 
2.2.1.1 Thioacetamide induced hepatotoxicity model 
Thioacetamide (Figure 2.3), originally used as a fungicide, is potent hepatotoxin bio-
activated by cytochrome P450 to sulfine (sulfoxide) and sulfene (sulfone) metabolites; it 
is known to induce liver cirrhosis in rats, which is caused by free radical-mediated lipid 
peroxidation. Thioacetamide administration leads to liver damage in rats marked by 
increase ALT, AST in serum and malondialdehyde (MDA) in liver, also centrilobular 
necrosis in hepatic architecture (Ahmad et al., 1999). Thioacetamide interferes with the 
movement of RNA from the nucleus to cytoplasm which may cause membrane injury. 
A metabolite of thioacetamide is responsible for hepatic injury. Thioacetamide reduce 
the number of viable hepatocytes as well as rate of oxygen consumption. Usually TAA 
dosage is 100 to 300 mg/kg, administrated subcutaneous (S.C) or intraperitoneal (I.P) 
(Ahmad et al., 2002; AydIn et al., 2009; Madani et al., 2008). Long term administration 
and/or high doses of TAA results in a biochemical changes, histological and 
characteristic lesion in rat liver, which corresponds to cirrhosis-like patterns of micro 
nodular liver cirrhosis in humans and associated protein-energy malnutrition. 
Investigation on therapeutic principles should be done during thioacetamide 
24 
 
administration (prophylactic agents) or within 2 months after withdrawal of toxic agents 
(therapeutics) (Muller et al., 1988; Zimmermann et al., 1987).  
 
 
Figure 2.3 Thioacetamide chemical structure 
 
 
2.2.1.2 Carbon tetrachloride induced hepatotoxicity model  
Carbon tetrachloride is a strong hepatotoxin producing hepatic necrosis. Liver injury 
due to CCl4 in rats has been successfully used by many investigators (Ha et al., 2005). 
Carbon tetrachloride is metabolized by cytochrome P450 in endoplasmic reticulum and 
mitochondria with the formation of a highly reactive trichloromethl and trichloromethyl 
peroxy free radicals, which initiate lipid peroxidation and finally cell necrosis 
(Vlacheva-Kuzmanova et al., 2004). Administration of a single dose of CCl4 to a rat 
produces, within 24 hrs, a centrilobular necrosis and fatty changes. The development of 
necrosis is associated with the leakage of hepatic enzymes into serum.  Dose of CCl4 is 
0.1 to 3 ml/kg administrated intraperitoneally (Handa & Sharma, 1990; Parola et al., 
1992a).  
 
2.2.1.3 Paracetamol induced hepatotoxicity model  
Paracetamol, a widely used analgesic and antipyretic drug, produces acute liver damage 
in high doses (Bhanwra et al., 2000). Paracetamol administration causes necrosis of the 
centrilobular hepatocytes characterized by nuclear pyknosis and eosinophilic cytoplasm 
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followed by large excessive hepatic lesion. The covalent binding of N-acetyl-P-
benzoquinoneimine, an oxidative product of paracetamol to sulphydryl groups of 
protein, result in degradation and lipid peroxidation of glutathione level and thereby, 
produces cell necrosis in the liver. Dose of Paracetamol is 1 to 2 gm/kg administrated 
orally (Bhanwra et al., 2000; Maheswari et al., 2008). 
2.2.2 In vitro methods 
In vitro assays using cultured liver cell line is more convenient, because it allows more 
samples be tested, is less costly regarding animals, and gives more reproducible results. 
Identification of active compounds of plants with known hepatoprotective properties 
requires screening of large numbers of samples obtained during fractionation and 
purification processes. Because of the expense and the time involved, the use of animal 
models or freshly isolated hepatocytes is not convenient for this large-scale screening of 
material separated from crude plant extracts. Thabrew et al. (1997) introduced a 
reproducible microplate-screening assay based on protection of liver cells line against 
toxic damage that can be used for rapid identification of active fractions of plant extract. 
Cell lines offer the unique possibility to elucidate interactions with vital cellular 
functions such as metabolism, cell growth, and death that were formerly difficult to 
address (Gebhardt, 2000). Either isolated rat hepatocyte cells or primary cultured 
hepatocytes are used to study the hepatoprotective effect of drugs. Most investigators 
obtain their established cell lines from cell banks such as American Type Culture 
Collection (ATCC). These cell lines often retain many features of the primary cell lines, 
are usually well documented and well characterized for specific experimental purposes. 
The cells treated with the hepatotoxin such as H2O2 and the effect of plant extract is 
evaluated. Parameters such as cell viability, morphology, antioxidant defence imbalance 
and oxidative stress are determined (Bladier et al., 1997; Huang et al., 1999). 
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2.2.3 Markers for hepatoprotective activity evaluation 
Several parameters are used to evaluate the effect of drug on liver:  
1. Biochemical blood analysis of liver markers: ALT, AST, ALP and bilirubin. 
When the liver cell is injured or dies, ALT, AST, ALP can leak through the liver 
cell membrane into the circulation and serum levels will rise. Bilirubin level 
rises in diseases of hepatocytes, obstruction to biliary excretion into duodenum, 
in hemolysis and defects of hepatic uptake and conjugation of bilirubin 
treatment.  
2. Gross liver examination: for macroscopic abnormal morphology. 
3. Histopathology examination of the liver: for microscopic abnormalities and 
changes. 
4. Serum protein: liver cells synthesize total proteins, albumin and alpha 
fetoproteins. The blood levels of these plasma proteins are decreased in 
extensive liver damage. 
5. Coagulation factors: fibrinogen, prothrombin, and other coagulation factors 
reduced in liver damage, which they are measured direct or through prothrombin 
time.  
6. Relative liver weight: (liver weight/body weight) percentage. 
7. Level of the antioxidant enzymes: superoxide dismutase (SOD), glutathione 
peroxidase (GPx), and catalase to evaluate the antioxidant defense status, using 
liver homogenates. 
8. Level of oxidative stress and lipid peroxidation: by measuring the MDA. 
9. Gene expression: to study the mechanism of action for hepatoprotective activity 
on the genetic level changes.  
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2.2.4 Silymarin  
Silymarin (Figure 2.4) is a chemical constituent isolated from the seeds of milk thistle 
(Silybum marianum) exhibits protective effects against induced hepatotoxicity in rats. 
The flavonolignan mixture can protect from liver cirrhosis. It is a mixture of mainly 3 
flavonolignans isomers, i.e. silybin, silydianin and silychristine, with silybin being the 
most active component and is largely responsible for the claimed benefit of the 
silymarin (Kvasnička et al., 2003). Silymarin has been used to treat toxic liver disease 
and for the supportive treatment of chronic active hepatitis and hepatic cirrhosis (Flora 
et al., 1998). Silymarin has drawn increasing attention because of its antifibrogenic 
properties; it reduces collagen accumulation by 30 % in secondary biliary fibrosis in 
rats. Due to its antioxidant activity it decreases hepatic injury by both cytoprotection 
and inhibition of indicated a slight survival advantage of treated compared with 
untreated controls (Li & Friedman, 1999). Its mechanisms of action include inhibition 
of hepatotoxin binding to receptor sites on the hepatocytes membrane, reduction of 
glutathione oxidation to enhance its level in the liver and intestine, antioxidant activity, 
free radical scavenging properties, anti-inflammatory, anti-fibrotic effects and 
stimulation of ribosomal RNA polymerase and subsequent protein synthesis leading to 
enhanced hepatocyte regeneration. It is orally absorbed, but has very poor 
bioavailability due to its poor water solubility (Kshirsagar et al., 2009). 
Hepatoprotective activity of silymarin has been demonstrated by various researchers 
against toxic models in experimental animals by using TAA, paracetamol, CCl4 and 
ethanol (Dixit et al., 2007; Ghosh et al., 2010; Pradhan & Girish, 2006). 
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Figure 2.4 Chemical structure of the main isomer of silymarin (silybin) 
 
2.3 Antioxidant activity 
2.3.1 Free radicals and reactive oxygen species  
Free radicals are chemical compounds which contain unpaired electrons in their outer 
electron orbit. The free radicals are energetic and highly unstable, in order to gain 
stability, they always seek other electrons to pair with, they attack and steal electrons 
from other molecules such as lipids, proteins, DNA and carbohydrates. Even they can 
damage DNA and lead to mutation and chromosomal damage. The attacks molecule 
loses its electron and becomes free radicals itself, this initiates an uncontrolled chain 
reaction that can damage the natural function of the living cell, resulting in various 
diseases (Valko et al., 2006). The free radicals can be classified as reactive oxygen 
species (ROS) or reactive nitrogen species. ROS are the most important free radicals in 
our body and it refers to any free radical involving oxygen-centered free radical 
containing two unpaired electrons in outer shell. There are two sources of free radicals 
namely endogenous and exogenous sources. Endogenous sources include free radicals 
produced during nutrient metabolism and energy production in the mitochondria 
(Bergendi et al., 1999). Another endogenous source of ROS, especially in the liver, is a 
group of enzymes called the cytochrome P450 mixed–function oxidases. The 
biochemical reactions catalyzed by the cytochrome P450 molecules use molecular 
oxygen, and during these reactions small amounts of ROS are generated. The extent of 
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ROS generation may vary considerably depending on the compound to be degraded and 
on the cytochrome P450 molecule involved. One type of cytochrome molecule that is 
especially active in producing ROS is known as cytochrome P450 2E1 (CYP2E1) 
(Lieber, 1997). The exogenous sources come from the environmental contaminants such 
as smoking, toxic chemicals, radiation, air pollution, organic solvents and pesticides 
(Büyükokuroğlua et al., 2001). Free radicals are involved in many physiological 
processes and human diseases such as cancer, arteriosclerosis, aging, arthritis, 
Parkinson syndrome, ischaemia, toxin induced reaction, alcoholism and liver injury 
(Willcox et al., 2004). The damage to hepatic parenchymal cells, leading to hepatic 
injury, is due to oxidative stress within the cells caused by partially reduced free oxygen 
species such as superoxide anions, hydroxyl radicals, hydrogen peroxide and singlet 
oxygen (Halliwell, 1995). The elevation of free radical levels seen during the liver 
damage is due to enhanced production of free radicals and decreased scavenging 
potential of the cells. Natarajan et al suggested that evidence of oxygen free radicals is 
also found early in the development of fibrosis and cirrhosis (Natarajan et al., 2006).  
 
2.3.2 Oxidative stress in liver cirrhosis 
Oxidative stress is an imbalance between the excessive formation of ROS and 
endogenous antioxidants, which may lead to cell injury. While large levels of ROS are 
attained, which may induce severe oxidation of biomolecules and dysregulation of 
signal transduction and gene expression, leading to cell death through necrotic and/or 
apoptotic mechanisms (Dröge, 2002). Undoubtedly ROS production and excessive 
oxidative stress in liver cells contributes to the progression and pathological findings of  
liver cirrhosis and finally to hepatocellular carcinoma, regardless of the etiology (viral 
infection, alcohol consumption, and drug overload) and serves as a link between hepatic 
injury and fibrosis (Halliwell, 1999; Zhu et al., 2012). Liver fibrosis due to chronic 
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ethanol intoxication is always accompanied by indices of excessive oxidation of 
polyunsaturated membrane lipids. The pro-oxidant effect of ethanol has been clearly 
demonstrated to be dependent upon alcohol metabolism, and in particular to the 
induction of a defined isoform of the cytochrome P450 family, namely the CYP2E1 
(Ekstrom & Ingelman-Sundberg, 1989). On the other hand, oxidative stress seems to be 
responsible for the progression of the activation of HSC, TGF-β induction and collagen 
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during chemical-induced fibrogenesis (Albano, 2000; Kim et al., 2000). Under 
the conditions of excessive oxidative stress, the aldehydes formed from membrane lipid 
peroxidation (e. g., malondialdehyde and 4-hydroxynonenal) attack various cellular and 
extracellular proteins in the hepatocytes and stimulate the progression of collagen 
deposition in the inflamed tissue (Albano, 2006). They seem to affect gene expression 
in adjacent HSC as demonstrated by the induction of matrix components (collagen type 
I, fibronectin), matrix metalloproteinases and other factors (Svegliati-Baroni et al., 
2001). 
 
2.3.3 Antioxidant and liver cirrhosis 
Antioxidants are compounds that dispose, scavenge and suppress the formation of free 
radicals, or oppose their actions. Generally, antioxidants scavenge free radicals through 
four mechanisms. The first mechanism involves termination of free radicals production 
by electron donation. In the second mechanism, ROS initiator is removed by 
antioxidant. The third mechanism is by reducing the potency of ROS. Antioxidant 
serves as transition metal catalysts chelating agent in the fourth mechanism. 
Antioxidants protect the human body against free radical attacks that may cause 
pathological conditions such as liver cirrhosis (Hasani-Ranjbar et al., 2009). 
Antioxidants, particularly those of plant origin, have emerged as potent antifibrotic and 
hepatoprotective agents. Moreover, lipid peroxidation was significantly increased along 
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with significant decrease in antioxidant levels in patients with alcoholic liver disease 
(Shinde & Ganu, 2009). In recent years there has been increasing interest in the 
presence and availability of compounds in plant materials that may possess bioactive 
properties, in particular, antioxidant activity. Plant antioxidants are composed of a broad 
variety of different substances like polyphenolic compounds, tocopherols or terpenoids. 
Most antioxidants isolated from higher plants are phenolic compounds (e.g. phenolic 
acids, tannins, coumarins, anthraquinones, flavonoids) (Middleton Jr & Kandaswami, 
1994). The antioxidant activity of phenolic compounds was found to be mainly due to 
their scavenging and redox properties, through neutralizing and quenching free radicals 
(Galato et al., 2001). Several anti-inflammatory, anti-necrotic, and hepatoprotective 
drugs have recently been shown to have an antioxidant and/or anti-radical scavenging 
mechanism as part of their activity. Cells are equipped with different kinds of cellular 
enzymes and compounds that may stand for to fight against ROS and to maintain the 
redox homeostasis of cell. For example, antioxidant enzymes such as superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) play important 
roles in scavenging the free radicals and preventing cell injury. Molecules such as 
vitamin C and E inhibit lipid peroxidation in cell. When the mechanism of antioxidant 
protection becomes unbalanced in human body, antioxidant supplement may be used to 
help reduce oxidative damage (Bergendi et al., 1999). 
 
2.3.4 Evaluation of antioxidant activity 
In vitro and in vivo antioxidant models were used to assess the antioxidant potential of 
the herbal extract. A great number of in vitro methods have been developed to measure 
the efficiency of natural antioxidants either as pure compounds or as plant extracts.  
Electron transfer reactions are the most famous In vitro methods, like trolox equivalent 
antioxidant capacity, ferric reducing antioxidant power (FRAP), α, α-diphenyl-β-picryl-
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hydrazyl radical scavenging assay (DPPH), hydroxyl radical scavenging assay, nitric 
oxide radical scavenging assay and total phenol content. These methods are popular due 
to their high speed and sensitivity. However, it is essential to use more than one method 
to evaluate antioxidant capacity of plant materials because of the complex nature of 
phytochemicals (Chanda & Dave, 2009). In addition to the in vitro assay that can be 
carried out on plant extracts, there are many in vivo cellular enzymes and compounds 
may achieve on experimental animal tissue homogenate such as SOD, CAT, GPx and 
MDA, which is indicate the lipid peroxidation status (Pietrangelo et al., 1995).  
 
2.4 Immunomodulatory activity 
An immunomodulator is a substance used for its effect on the immune system, which 
can suppress, stimulate or modulate the immune system. The immunostimulants are 
investigated to enhance body’s immunity against infection, allergy, autoimmunity and 
cancer. In healthy individuals the immunostimulants are expected to serve as 
prophylactic by enhancing the basal levels of immune response, while in individuals 
with impairment of immune response as immunotherapeutic agent (Agarwal & Singh, 
1999). Some medicinal plants and their active components such as Ginseng, Echinacea 
and Astragalus possess immunomodulatory properties and show potential against 
malignant diseases and infections (Block & Mead, 2003). Blood mononuclear cells 
including natural killer (NK) cells have an important function in the defence against 
bacterial infections, virus-infected cells and malignant cells. High frequency of 
infections and cancer development are always related to the reduction of NK cell 
number or cytolytic activity (Lotzová, 1991). The in vitro methods used to study 
immunomodulation are principally based on the assessment of the proliferation, the 
metabolic activity and the activation of immune cells (measurement of cytokine 
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production). The most common method used to investigate the immunomodulatory 
properties of new compounds is the one using the human peripheral blood mononuclear 
cells (PBMCs) or mice splenocytes as target cells (Ajaya Kumar et al., 2004; Swamy & 
Tan, 2000). The activation of PBMCs proliferation is always related to the 
immunomodulating potential of the extract. A few methods are being widely used to 
evaluate the immunomodulating activity based on the assessment of the proliferation, 
metabolic activity [such as 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay] and cell number quantitation (direct cell counting using a 
hemocytometer) (Durrieu et al., 2005). 
 
2.5 Antibacterial activity 
Nowadays bacterial infections have increased all over the world and antibiotics 
resistance has emerged as a challenging therapeutic problem, therefore screening of 
medicinal plants to discover new antibacterial agents has gained priority (Austin et al., 
1999). The use of plant extracts and phytochemicals, both with known antimicrobial 
properties, can be of great significance in therapeutic treatments. In the last few years, a 
number of studies have been conducted in different countries to prove such efficiency 
(Nascimento et al., 2000). Resistance to antimicrobial agents has resulted in morbidity 
and mortality from treatment failures and increased health care costs. The association 
between increased rates of antimicrobial use and resistance has been documented for 
nosocomial infections as well as for resistant community acquired infections. The problem 
of microbial resistance is growing and the outlook for the use of antimicrobial drugs in 
the future is still uncertain. Therefore, actions must be taken to reduce this problem, for 
example, to control the use of antibiotic, develop research to exact understand the 
genetic mechanisms of resistance, and to continue studies to develop new drugs, either 
synthetic or natural. The ultimate goal is to offer appropriate and efficient antimicrobial 
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drugs to the patient (Nascimento et al., 2000). Natural products of higher plants 
represent a rich source of antimicrobial agents with possibly novel mechanisms of 
action. Contrary to the synthetic drugs, antimicrobials of plant origin are not associated 
with many side effects and have an enormous therapeutic potential to heal many 
infectious diseases (Iwu et al., 1999). The most widely used screening methods to 
measure the antibacterial efficacy of a compound or medicinal plant and their 
constituents are both disc diffusion and minimum inhibitory concentration (MIC) 
against bacterial strains (NCCLS, 2000). In disk diffusion test, dried- filter paper 
impregnated with a specified amount of drug are applied to the service of an agar 
medium inoculated with the microorganism. The compound in the disk diffuses through 
the agar creating inhibition zone around the disk, the larger the zone diameter, the lower 
the MIC. Moreover, the strength of the antimicrobial activity can be determined by 
dilution of compound in agar or broth. In dilution susceptibility test, serial dilution of 
the extract in a number of test tubes contain media broth followed by addition of test 
microorganism to determine the MIC for the microorganism using the turbidity as 
indication of growth. The determination of the lowest concentration of an antimicrobial 
agent needed to inhibit the growth of microorganism being tested called MIC, where is 
no visible growth in a nutrient medium. However, the minimum bactericidal 
concentration (MBC) is the lowest concentration of an antimicrobial agent where the 
culture has been completely sterilized after subculture onto antibiotic-free media. While 
agar diffusion method is excellent for screening compounds, the MIC is better for 
determination the exact inhibitory concentration. The broth micro-dilution method was 
used to determine the MIC according to the National Committee for Clinical Laboratory 
Standards guidelines (NCCLS, 2003). 
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2.6 Investigated medicinal plants  
 
2.6.1 Orthosiphon stamineus 
Orthosiphon stamineus Benth (Family: Lamiaceae), also known as Misai Kucing in 
Malaysia, kumis kucing in Indonesia, and Java tea in Europe, this is native plant to 
South East Asia (Indubala & Ng, 2000). 
 
2.6.1.1 Description  
O. stamineus (Figure 2.5) is a herbaceous perennial that bears 3-6 long flower spikes 
from summer to fall, which grows to a height of 1.5 m. The flowers are hermaphrodite 
in nature, white and airy with long white stamens that look like cat whiskers, hence the 
common name. Cat whiskers can reach 18-24 in height and double that in width and is a 
great asset to attract wildlife into the garden. O. stamineus will do great in full to 
partially sunny areas as long as it does not dry out. In the wild, it can be seen growing 
along the forest edges, roadsides and wastelands. The leaves are arranged in opposite 
pairs. They are simple, green, and glabrous with a lanceolate leaf blade and a serrate 
margin. The leaf apice is acuminate with an acute leaf base. The petiole is relatively 
short, about 0.3 cm in length and reddish purple in color. The stem is quadrangle, 
reddish in color, erect and with profuse branching. Although it looks similar to 
peppermint, the plant has a dry, salty, bitter taste. The plant is found in an area 
extending from tropical Asia, China and Thailand through Malaysia to tropical 
Australia, and is a 40 to 80 cm high herb. The medicinal parts are the leaves and stem 
tips collected during the flowering season. Various herbal preparations (notably aqueous 
and ethanolic extracts) are used in traditional medicines (Wiart, 2002). 
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Figure 2.5 Orthosiphon stamineus Benth 
 
 
2.6.1.2 Uses, pharmacological properties and safety 
O. stamineus has been widely used in Malaysia as herbal tea , as diuretic, for treating 
kidney problems, fever, hypertension, abdominal pain, edema, gout, to treat 
rheumatism, diabetes, hepatitis, and jaundice (Basheer & Majid, 2010; Chin et al., 
2008b; Wiart, 2002). O. stamineus is listed in the French, Indonesia, Dutch, and Swiss 
pharmacopoeias for conditions related to renal cleansing and function, and related 
disorders that include nephritis, cystitis, and urethritis. In Europe, people use the leaves 
of O. stamineus extract as a tonic for kidney and bladder stones, liver and gallbladder 
problems and urinary tract infections. It is also used to reduce cholesterol and blood 
pressure. Researchers have found it to be mildly antiseptic as well. O. stamineus has 
been proven using animal models to treat diabetes mellitus and improving lipid proﬁle 
in diabetic rats (Sriplang et al., 2007), kidney problem diuretic and hypouricemic eﬀects 
in rats (Arafat et al., 2008), as anti-inﬂammatory (Yam et al., 2008), for the treatment of 
hypertension (Ohashi et al., 2000), and antipyretic activity (Yam et al., 2009). 
Moreover, the plant’s strong antioxidant action is what makes many researchers to 
explore the potential pharmacological properties of this plant. It has been scientifically 
proven that O. stamineus exhibits a range of pharmacological properties such as 
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antioxidant, antibacterial, cytotoxic, diuretic, antihypertensive and anti-angiogenesis 
properties (Basheer & Majid, 2010; Ho et al., 2010; Sahib et al., 2009). O. stamineus 
has been extensively studied in rodents with no signs of toxicity. In a study, researchers 
administered the botanical orally to rats for 14 days and compared it to a control group 
receiving distilled water. The four test groups were treated with 0.5 g/kg, 1 g/kg, 3 g/kg 
and 5 g/kg body weight of O. Stamineus respectively. No lethality or adverse toxic signs 
were seen during the experimental period. The study concluded that O. stamineus 
within these range and treatment duration would not cause any severe toxic effects and 
organ damage in rats. Individuals in Malaysia, Vietnam and Japan have consumed O. 
stamineus for centuries, further supporting its safety. Furthermore, recently the herb has 
been shown to be exceptionally safe with no toxicity in vitro and in vivo (Chin et al., 
2008b; Mohamed et al., 2011). 
 
 
2.6.1.3 Phytochemistry 
The literature review shows that this plant contains phenolic compounds and ﬂavonoids. 
More than twenty phenolic compounds were isolated from O. stamineus, the most 
important constituents are nine lipophilic ﬂavones, two ﬂavonol glycosides, and nine 
caﬀeic acid derivatives (Sumaryono et al., 1991). The well-known chemical 
constituents of O. stamineus (Figure 2.6) are caﬀeic acid, cirrchoric acid, diterpenes, 
orthosiphols, monoterpenes, triterpenes, saponins, hexoses, organic acids, rosmarinic 
acids, sinensetin, eupatorin, and 3-hydroxyl-5,6,7,4-tetramethoxyﬂavone (TMF) 
(Akowuah et al., 2005a; Olah et al., 2003; Tezuka et al., 2000). The plant contains high 
amount of flavones, polyphenols, bioactive proteins, glycosides, a volatile oil, and vast 
quantities of potassium. Earlier studies reported bioactive pentacyclic triterpenes 
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betulinic acid, oleanolic acid, ursolic acid and sterols from the leaves of this plant 
(Tezuka et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Chemical structures of the main phenolic compounds in   O. Stamineus 
 
2.6.2 Morinda citrifolia 
The genus Morinda (Family: Rubiaceae), including the species Morinda citrifolia L., is 
made up of around 80 species. M. citrifolia commercially known as noni, is indigenous 
to tropical countries and is considered as an important traditional folk medicine. Apart 
from this appellation, there are many local names that are also widely used in their 
respective countries namely, Mengkudu (Malaysia), Noni Apple, Polynesia Fruit, Indian 
Mulberry (India), Bumbo (Africa), Cheeserut (Australia), Painkiller Tree (Caribbean 
Islands), Nhau (Southeast Asia), Morinda (Vietnam), and Hai Ba Ji (China) (Chan-
Blanco et al., 2006). 
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2.6.2.1 Description   
M. citrifolia (Figure 2.7) is a shrub which grows in sandy areas along many tropical 
coastal regions at sea level and in forest areas of up to about 1300 feet above sea level. 
M. citrifolia is a bush or small evergreen tree, 3–10 m tall, with abundant wide elliptical 
leaves (5–17 cm length, 10–40 cm width). It can be identify by its straight trunk, large, 
bright green and elliptical leaves, white tubular flowers, and its distinctive, ovoid, 
“grenade-like” yellow fruit. The small tubular white flowers are grouped together and 
inserted on the peduncle. The petioles leave ring-like marks on the stalks and the corolla 
is greenish-white. The noni fruit (3–10 cm length, 3–6 cm width) is oval and fleshy with 
an embossed appearance. It is slightly wrinkly, semi-translucent, and ranges in colour 
from green to yellow, to almost white at the time of picking. It is covered with small 
reddish-brown buds containing the seeds. The pulp is juicy and bitter, light dull yellow 
or whitish, gelatinous when the fruit is ripe; numerous hard triangular reddish-brown 
pits are found, each containing four seeds (3.5 mm). The mature fruit has a foul taste 
and odour. M. citrifolia grows in shady forests, as well as on open rocky or sandy 
shores. It reaches maturity in about 18 months, then yields between 4 and 8 kg of fruit 
every month throughout the year. It is tolerant of saline soils, drought conditions, 
and secondary soils. It is therefore found in a wide variety of 
habitats: volcanic terrains, lava-strewn coasts, and clearings or limestone outcrops 
(Chan-Blanco et al., 2006).  
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Figure 2.7 Morinda citrifolia plant with fruit 
 
2.6.2.2 Uses, pharmacological properties and safety 
All parts of the plant have traditional and/or modern uses, including roots and bark 
(dyes, medicine), trunks (firewood, tools), leaves and fruits (food, medicine). The 
medicinal applications, both traditional and modern, span a vast array of conditions and 
illnesses, although most of these have yet to be scientifically supported (Chan-Blanco et 
al., 2006). The tree has attained significant economic importance worldwide in recent 
years through a variety of health and cosmetic products made from its leaves and fruits. 
These include fruit juices as well as powders made from the fruit or leaves. Fruit 
extracts have been traditionally used as a sedative, a remedy for diarrhoea, a topical 
disinfectant, and as a gargle to relieve sore-throat.  M. citrifolia  has been used in folk 
remedies by Polynesians for over 2000 years, and is reported to have a broad range of 
therapeutic effects, including antibacterial, antiviral, antifungal, anticancer, analgesic, 
hypotensive, anti-inflammatory, and immune enhancing effects (Akihisa et al., 2007; 
Anekpankul et al., 2007; Chan-Blanco et al., 2006; Wang et al., 2002). The fruit juice is 
in high demand as an alternative medicine for different kinds of illnesses such as 
jaundice, to alleviate menstrual cramps, arthritis, diabetes, gastric ulcers, sprains, poor 
digestion, problems associated with high blood pressure, muscle aches and pains, 
41 
 
headaches, heart disease, mental depression, senility and drug addiction. Scientific 
evidence on the benefits of the noni fruit juice is limited but there is some anecdotal 
evidence for successful treatment of colds and influenza (Wang et al., 2002). Extracts of 
M. citrifolia have been shown to possess several pharmacological properties, e.g. 
analgesic, anti-inflammatory, antioxidant, chemoprotective, antimicrobial, and 
immunomodulatory properties (Hirazumi et al., 1996; Wang et al., 2002). An acute 
toxicity studies were conducted for the M. citrifolia extract showed that the plant is save 
up to 4 g/kg body weight. All animals survived with no mortality and no any sign of 
toxicity were noted. No signs of gross toxicity were seen in the organs after necropsy 
(Nayak et al., 2009; Wang et al., 2002).  
 
2.6.2.3 Phytochemistry 
The fruit contains 90 % of water and the main components of the dry matter appear to 
be soluble solids, dietary fibers and proteins. The fruit protein content is surprisingly 
high, representing 11.3 % of the juice dry matter, and the main amino acids are aspartic 
acid, glutamic acid and isoleucine (Chunhieng, 2003). About 160 phytochemical 
compounds have been already identified in M. citrifolia, and the major micronutrients 
are phenolic compounds, organic acids and alkaloids. Of the phenolic compounds, the 
most important reported are anthraquinones (damnacanthal, morindone, morindin, etc.), 
and also aucubin, asperuloside, and scopoletin (Figure 2.8). The main organic acids are 
caproic and caprylic acids, while the principal reported alkaloid is xeronine (Wang & 
Su, 2001). The other major components have been identified in M. citrifolia  include 
octoanoic acid, potassium, vitamin C, terpenoids, alkaloids, anthraquinones (such as 
nordamnacanthal, morindone, rubiadin, and rubiadin-1-methyl ether, anthraquinone 
glycoside), β-sitosterol, carotene, vitamin A, flavone glycosides, linoleic acid, alizarin, 
amino acids, acubin, L-asperuloside, caproic acid, caprylic acid, ursolic acid, rutin, and 
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a putative proxeronine, while the fruit juice contains a polysaccharide rich compounds 
(Farine et al., 1996; Hirazumi et al., 1994; Jayaraman et al., 2008; Levand & Larson, 
1979).  
 
 
 
 
 
 
Scopoletin     Morindone 
Figure 2.8 Chemical structures of the main phenolic compounds in M. citrifolia fruits  
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CHAPTER III 
METHODOLOGY 
 
3.1 Plant materials and chemicals 
O. stamineus plant leaves and M. citrifolia plant fruits (Table 3.1) were obtained from 
the Ethno Resource Sdn Bhd Selangor, Malaysia. The plants were identiﬁed, and 
voucher specimens were kept in our laboratory for future references. Totally 100 gm of 
the dried and fine powdered of plant were extracted with 900 ml of 95 % ethanol for 48 
h, after that the residue was extracted two times again with 95 % ethanol. The ethanol 
extracts were ﬁltered by filter paper (Whatman No. 1) and evaporated under low 
pressure by using rotary evaporator (Buchi, type R-215, Rotavapor, Switzerland) and 
finally subjected to lyophilization in freeze dryer (LabConco, Kansas City, MO, USA) 
to give the crude-dried extract. The percentage yields of ethanol extracts for O. 
stamineus and M. citrifolia were found to be 8.1 % and 16.0 % (w/w) respectively. The 
dried extracts were stored at -20°C until used  (Alshawsh et al., 2011). Thioacetamide 
from (Sigma-Aldrich, Switzerland), silymarin from (International Laboratory, USA) 
and all other chemicals used were of analytical grade and purchased mostly from 
Sigma-Aldrich, UK and Fisher Scientific, UK. 
 
Table 3.1 Investigated Medicinal plants  
Botanical name Local name Family Part tested Traditional uses 
Orthosiphon stamineus 
Benth 
Misai kuching Lamiaceae Leaves Hepatitis and jaundice, 
kidney problems, fever, 
hypertension, gout, 
diabetes 
 
Morinda citrifolia L. Mengkudu 
 
Rubiaceae fruits Tonic, skin wounds and 
abscesses, Antipyretic, 
gum and throat 
problems, constipation 
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3.2 Experiment design  
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3.3 Antioxidant activity 
The investigated plants examined to determine their antioxidant activity using the 
following assays; DPPH, FRAP, total phenolic content (TPC) and flavonoid content 
(FC). 
 
3.3.1 Scavenging activity of DPPH   
The antioxidant activities of the crude extracts were determined using 2, 2-Diphenyl-1-
picrylhydrazyl (DPPH) free radical scavenging assay. DPPH is a molecule containing a 
stable free radical. In the presence of an antioxidant which can donate an electron to 
DPPH, the purple color which is typical for free DPPH radical decays and the change in 
absorbency at 515 nm can be read. This assay measures the free radical scavenging 
capacity of the investigated extracts. The assay was carried out as described by Brand et 
al (Brand-Williams et al., 1995) with minor modification. Briefly 1 mg from ethanolic 
and aqueous extracts dissolved in 1 ml solvent then diluted to got five different 
concentrations (25, 12.5, 6.25, 3.125 and 1.56 µg/ml) and Ascorbic acid used as 
antioxidant standards. A quantity of (5 µl) from each plant extract and standard were 
mixed with 195 µl of DPPH (40 X dilution) in triplicate. The decrease in absorbance 
value was measured at 515 nm for 2 hr with 20 min intervals. The radical scavenging 
activity was calculated from the following equation and the results were expressed as 
mean ± standard error mean (SEM): 
% of radical scavenging activity = (Abs Blank – Abs Sample) /Abs Blank X100 
 
3.3.2 Ferric reducing antioxidant power (FRAP) assay 
The ferric reducing activity of the plant extracts were estimated using with some 
modification the method developed by (Benzie & Strain, 1996). The reaction mixture 
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contained 300 mmol/l acetate buffer, 10 mmol/l TPTZ (2, 4, 6-tripyridyl-s-triazine) in 
40 mmol/l of HCl acid and 20 mmol/l of FeCl3. 6H2O. The working FRAP reagent 
prepared freshly by mixing 25 ml of acetate buffer, 2.5 ml of TPTZ solution and 2.5 ml 
of FeCl3. 6H2O. The freshly prepared mixture was incubated at 37°C in water bath for 
five minutes and then a blank reading was taken spectrophotometrically at 593 nm. 
After that, 10 µl of extract or standard were added to 300 µl of the working FRAP 
reagent. Absorbance is measured at 0 minute immediately upon addition of the working 
FRAP reagent after mixing. Thereafter, absorbance reading was taken after four 
minutes. The standard curve was plotted using FeSO4 solution absorbance as standard, 
and the results were expressed as μmol Fe(II)/g dry weight of crude extract (appendix 
IV). 
 
3.3.3 ABTS assay 
The total antioxidant capacity assay was carried out using the improved method, as 
described by (Re et al., 1999). Briefly, 2, 2'-azino-bis-(3-ethylbenzothiazoline-6-
sulphonic acid (ABTS) radical cation is generated by reacting 7 mM ABTS and 2.45 
mM potassium persulfate via incubation at room temperature, in the dark for 12–16 h. 
The ABTS solution was diluted with methanol to reach to the absorbance of 0.700 ± 
0.020 at 734 nm and equilibrated at 30°C while plant extracts were diluted with distilled 
water. To 1 ml of diluted ABTS, 10 µl of each plant extract solution were added and 
mixed thoroughly. The reactive mixture was allowed to stand at room temperature for 
15 min and the absorbance was recorded immediately at 734 nm. 
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3.3.4 Total phenolic content (TPC) and flavonoids determination 
The O. stamineus and M. citrifolia extracts were evaluated for their total phenolic 
content by using Folin-Ciocalteu reagent and were calculated as gallic acid equivalents 
in mg (GAE)/g of extract according to Folin-Denis colorimetric method (AOAC, 
1995).  However, the total flavonoids were determined by using the aluminium chloride 
colorimetric method, and expressed as quercetin equivalents in mg (QE)/g of extract as 
described by Dowd (Dowd, 1959). Both assays were carried out in triplicate. 
 
3.4 Acute toxicity  
Three groups of 10 adult Sprague–Dawley (SD) rats (5 males and 5 females) were given 
single oral doses of 5 g/kg body weight of the crude extract, 2 g/kg body weight of the 
crude extract and the control group received single dose of vehicle at the same volume. 
Observations for any abnormal behavioural pattern, clinical signs and mortality were 
made systematically for 48 h after doses administration and at the end of this period 
mortality was recorded for each group. The number of survivors was then maintained 
for a further 14 days. The last day of the experiment, all surviving animals were 
sacrificed then liver and kidney organs were collected, gross necropsy and 
histopathology examined (Lorke, 1983; OECD, 2001). The acute toxicity protocol was 
approved by Animal Ethics Committee; with an ethic No. (PM /07/05/2008/1111/ MAA 
(a) (R).  
3.5 In vivo hepatoprotective activity of plant extracts 
3.5.1 Animals  
Adult male healthy SD rats weighing 200-250 gm were obtained from Animal House 
Unit, Faculty of Medicine, University of Malaya, Malaysia. They were kept in wire 
bottomed cages at 25 ± 3
o
C temperature, 50-60 % humidity, and a 12 h light–dark cycle 
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for at least a week before the experiment. They were maintained at standard housing 
conditions and free access to standard diet and water ad libitum during the experiment. 
The experimental protocol was approved by Animal Ethics Committee; with an ethic 
No. (PM 28/08/2009/ MAA (R) (appendix I). Throughout the experiments, all criteria of 
taking care of animals prepared by the National Academy of Sciences and outlined in 
the “guide for the care and use of laboratory animals” were applied (Clark et al., 1997).  
 
3.5.2 In vivo hepatoprotective activity experimental design 
The dry extract was dissolved in Tween 20 (10 % w/v) and administered orally to rats in 
concentrations of 200 mg/kg high dose (HD) and 100 mg/kg low dose (LD) body 
weight. The TAA chemical was dissolved in sterile distilled water and injected 
intraperitoneally to the rats in concentrations of 200 mg/kg body weight (AydIn et al., 
2009). Silymarin as a standard drug was dissolved in Tween 20 (10 %w/v) and orally 
administered to rats in concentrations of 50 mg/kg body weight (Ahmad et al., 2002). 
For each plant the animals were randomly divided into five groups of eight rats each 
and treated for 2 months the doses administrated showed in (Table 3.2). Body weights 
of all animals were measured every week. All rats were sacrificed 24 hours after last 
treatment and overnight fasting under anesthesia. Blood samples were collected; serum 
was separated for assay of the liver biomarkers. The liver and spleen were harvested, 
washed in normal saline, blotted with filter paper and weighed. Gross examination was 
conducted to examine of any abnormalities developed in the organs. The liver of all 
animals was subsequently subjected to histopathological examination in a blinded 
fashion. 
 
 
49 
 
Table 3.2 In vivo hepatoprotective activity of plant extracts experimental design 
 
3.5.3 Biochemical and histopathological examination  
The collected blood samples were separated at 2500 rpm for 15 minutes after been 
completely become clotted. Serum for assay of the liver biomarkers such as aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), 
bilirubin, total protein (TP), and albumin was assayed spectrophotometrically by 
standard automated techniques according to the procedures described by the 
manufacturers in Central Diagnostic Laboratory, University of Malaya Medical Centre 
(appendix IV). The Liver was sliced and pieces and placed in tissue cassettes using a 
scalpel and forceps. Each tissue cassette labeled and fixed for 4 h in 10 % buffered 
formalin solution (appendix II) for histological study. The fixed tissues were 
dehydrated, cleared and infiltrated in automated tissue processing machine (Leica 
Microsystems, Nussloch, Germany) using standard technique (appendix II). Tissues 
were embedded in paraffin wax by conventional methods. Sections of 5 µm in thickness 
were cut using the microtome (Leica Microsystems, Nussloch, Germany) and then 
stained with hematoxylin-eosin (H&E) staining according to the standard protocol 
(appendix II). Then the stained sections were observed under the light microscope 
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(Olympus, Tokyo, Japan) for histopathological changes, and their photomicrographs 
were captured with a Nikon microscope digital camera (Nikon, Tokyo, Japan).  
 
3.6 In vivo antioxidant activity in liver tissue 
Liver samples were washed immediately with ice cold saline to remove the blood. Liver 
homogenates (10 % w/v) were prepared in a cold 50 mM potassium phosphate buffer 
saline (PBS) (pH 7.4) using homogenizer in ice (Wise Mix HG-15, Daihan Scientific, 
Seoul, Korea). The cell debris was removed by centrifugation at 4500 rpm for 15 min at 
4°C using refrigerated centrifuge Rotofix 32 (Hettich Zentrifugen, Germany). The 
supernatant was used for the estimation of the following in vivo antioxidant using 
commercially available kits from (Cayman Chemical Company, USA): total antioxidant 
capacity (TAC) (Item No. 709001), malondialdehyde (MDA) or thiobarbituric  acid 
reactive substance (TBARS) (Item No. 10009055), catalase (CAT) (Item No. 707002), 
superoxide dismutase  (SOD) (Item No. 706002) and glutathione peroxidase (GPx)  
(Item No. 703102) activities. All assays performed according to the instruction manual 
of the manufacturer (appendix III). Protein concentration was determined by the 
Bradford method using bovine serum albumin as a standard (Bradford, 1976).  
 
3.7 Gene expression assay using real time PCR (RT-PCR) 
Liver samples after sacrificing the rats were kept immediately in the preservative RNA 
later Soln. (Ambion, Austin, Texas, USA) and kept at 4
o
C overnight, after that stored in 
-80
o
C until used. The selected genes for the expression assay were; TGF-β, TIMP-1, 
MMP-2 and collagen1α1.  
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3.7.1 RNA isolation and purification  
Total RNA was extracted from liver tissue with QIAamp RNA Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol (appendix III). A DNase 
digestion step was included to eliminate genomic DNA contamination using the RNase-
Free DNase Set (cat. no. 79254) (Qiagen, Hilden, Germany) (appendix III). The RNA 
concentration was measured spectrophotometrically with a Nano Drop ND-2000 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). The ratio of the 
readings at 260 nm and 280 nm (A260/A280) provides an estimate of the purity of RNA 
with respect to contaminants that absorb in the UV, such as protein. Pure RNA has an 
A260/A280 ratio of 1.7–2.1 (appendix IV). The integrity and size distribution of total 
RNA purified with QIAamp RNA Mini Kits was checked by denaturing agarose gel 
electrophoresis and ethidium bromide staining (appendix II) using agarose gel 
electrophoresis apparatus (Bio-Rad, Richmond, CA, USA). The apparent ratio of 28S 
RNA to 18S RNA should be approximately 2:1 (Figure 3.1). The extracted RNA was 
stored at −80ºC until used.  
 
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 RNA profile using ethidium bromide-stained agarose gel   
 
3.7.2 Reverse transcription and cDNA synthesis 
One microgram of total RNA was reverse transcribed to cDNA using High capacity 
RNA-to-cDNA Master Mix (Applied Biosystems, Foster City, CA, USA) according to 
 
5       6      7       8     9     10    11     12 
28S 
 
18S 
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the manufacturer’s protocol (appendix III). The following total volumes of components 
were prepared to obtain total volume of 20 µl of cDNA per reaction as in (Table 3.3): 
 
Master Mix   4.0 μl 
RNA template Variable (up to 16 μl), calculated according to RNA 
concentration in order to obtain 1µg cDNA per reaction 
(Table 3.3) 
Nuclease-free H2O  sufficient to 20 μl 
 
All components were mixed well and loaded in a thermal cycler (Major Science, CA, 
USA) under the following conditions: 5 minutes at 25
°
C, then 30 minutes at 42
°
C, in 
step three 5 minutes at 85
°
C, finally holding at 4
°
C. The cDNA was stored at –20ºC until 
used. 
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Table 3.3 Reverse transcription components volume calculation 
Sample 
RNA 
Concentration 
ng/µl 
RNA volume 
µl 
Nuclease-free H2O 
µl 
Calibrator 1 647 1.6 14.4 
Calibrator 2 329 3.0 13.0 
Calibrator 3 503 2.0 14.0 
Calibrator 4 464 2.2 13.8 
Calibrator 5 641 1.6 14.4 
Calibrator 6 516 1.9 14.1 
Calibrator 7 879 1.1 14.9 
TAA 1 225 4.4 11.6 
TAA 2 577 1.7 14.3 
TAA 3 281 3.6 12.4 
TAA 4 522 1.9 14.1 
TAA 5 884 1.1 14.9 
TAA 6 724 1.4 14.6 
TAA 7 284 3.5 12.5 
O. stamineus 1 76.9 13.0 3.0 
O. stamineus 2 130 7.7 8.3 
O. stamineus 3 276 3.6 12.4 
O. stamineus 4 279 3.6 12.4 
O. stamineus 5 482 2.1 13.9 
O. stamineus 6 364 2.8 13.2 
O. stamineus 7 248 4.0 12.0 
M. citrifolia 1 554 1.8 14.2 
M. citrifolia 2 551 1.8 14.2 
M. citrifolia 3 556 1.8 14.2 
M. citrifolia 4 575 1.7 14.3 
M. citrifolia 5 316 3.2 12.8 
M. citrifolia 6 629 1.6 14.4 
M. citrifolia 7 541 1.9 14.1 
 
3.7.3 Real time PCR amplification  
The following TaqMan rat assay genes from (Applied Biosystems, Foster City, 
CA, USA) were used for RT- PCR: TGFβ1 (Rn00572010_m1), TIMP-1 
(Rn00587558_m1), MMP-2 (Rn01538167_m1) and Col 1a1 (Rn01463848_m1) (Table 
3.4). The NormFinder and geNorm algorithm (MultiD Analyses AB, Göteborg, 
Sweden) were used to evaluate and calculate the expression stability of four endogenous 
reference genes – HPRT-1 (Rn01527840_m1), Ppia (Rn00690933_m1), GAPDH 
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(Rn0177563_g1) and Act b (Rn00667869_m1) – for normalisation of rat’s liver samples 
(Chen et al., 2006a). According to the NormFinder algorithm, the gene that showed the 
lowest variability was HPRT-1, while geNorm showed that the HPRT-1 and Ppia are 
the best endogenous reference genes combination (appendix IV). The transcriptional 
levels of the target genes were normalized using both HPRT-1 and Ppia endogenous 
reference genes. These two genes were consistently expressed in rat liver tissue and 
experiments showed a stable expression of both endogenous reference genes in all 
groups. The cDNA was diluted with nuclease-free water (Applied Biosystems, Foster 
City, CA, USA) to a concentration of 20 ng/µl, after that 1 µl was applied for each RT-
PCR. The PCR was carried out using TaqMan fast advanced Master Mix (Applied 
Biosystems, Foster City, CA, USA) (appendix III). The volume and concentration of 
each component in the RT-PCR reaction mix was adjusted according to (Table 3.5). All 
components were added to 1.5 ml optical tube with cap (Applied Biosystems, Foster 
City, CA, USA). The amplification reaction was performed using the step one plus 
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to 
TaqMan gene expression assay protocol (appendix III) with the following cycling 
conditions: 2 min at 50°C, 20 sec at 95°C, followed by 40 cycles of 1 sec at 95°C and 
20 sec at 60°C. For each sample, the real-time PCR reaction was performed in triplicate, 
and the averages of the obtained threshold cycle (Ct) values were processed for further 
calculations according to the comparative Ct method. Gene expression values were 
calculated with the 2
-∆∆Ct
 method (Livak & Schmittgen, 2001). The ∆Ct value of each 
sample was determined by subtracting the average Ct value of the endogenous reference 
gene from the average Ct value of the target gene. The ∆∆Ct value was then calculated 
by subtracting the ∆Ct value of the treated sample from the control (untreated) ∆Ct 
value. Finally, the gene expression level was calculated as 2
-∆∆Ct
 giving the final value 
that is normalized to the reference genes and relative to the control sample values of the 
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studied genes. GenEx Enterprise software for quantitative real-time PCR (qRT-PCR) 
expression profiling (MultiD Analyses AB, Göteborg, Sweden) was used to analyze and 
normalize the qRT-PCR data (Kubista et al., 2006). This software allows the correction 
of PCR efficiencies and the normalization with more than one endogenous reference 
genes. Statistical analysis of differences was performed by a two-tailed unpaired 
Student’s t test. A p value of <0.05 was considered indicative of a statistically 
significant difference.  
  
Table 3.4 Investigated genes and reference genes with their Amplicon length, GenBank 
accession numbers and TaqMan gene expression assay numbers  
Gene 
Symbol 
Gene Name TaqMan gene 
expression 
assay number 
GenBank 
accession 
number 
Amplicon 
length 
TGFβ1 Transforming growth 
factor, beta 1 
Rn00572010_m1 NM_021578.2 65 
TIMP-1 Tissue inhibitors of 
metaloproteinases-1 
(metallopeptidase inhibitor 
1) 
Rn00587558_m1 NM_053819.1 91 
MMP-2 Matrix metaloproteinases-
2 (matrix metallopeptidase 
2) 
Rn01538167_m1 
 
NM_031054.2 72 
 
Col 1a1 collagen, type I, alpha 1 Rn01463848_m1 NM_053304.1 115 
HPRT-1 Hypoxanthine 
phosphoribosyl transferase 
1 (reference gene) 
Rn01527840_m1 NM_012583.2 64 
Ppia Peptidylprolyl isomerase 
A (cyclophilin A) 
(reference gene) 
Rn00690933_m1 NM_017101.1 149 
GAPDH Glyceraldehyde-3-
phosphate dehydrogenase 
(reference gene) 
Rn0177563_g1 NM_017008.3 175 
Act b 
 
Actin, beta (reference 
gene) 
Rn00667869_m1 NM_031144.2 91 
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Table 3.5 Components volume and concentration used in the RT-PCR reaction mix 
(total volume 10 µl) 
 
3.8 Immunomodulatory activity  
3.8.1 Peripheral blood mononuclear cell (PBMCs) isolation and cell culture 
Fresh blood was collected from healthy adult volunteer using heparinised tubes. 
Peripheral blood mononuclear cells (PBMCs) were separated by density-gradient 
centrifugation over Histopaque 1077 (Sigma-Aldrich, UK) (appendix III). The remnant 
erythrocytes in the recovered PBMCs layer were eliminated using lysis buffer to lysis 
the RBCs and washed three times in sterile PBS. The PBMC were re-suspended in 1 ml 
RPMI 1640 media (Sigma-Aldrich, UK). The mononuclear cells were counted and 
adjusted to an appropriate concentration in complete RPMI 1640 supplemented with 2 
mM glutamine, 1 % (v/v) Penicillin-Streptomycin antibiotic (Sigma-Aldrich, UK) and 
containing 10 % (v/v) fetal bovine serum (FBS) (J R Scientific, Inc, USA) for further 
assays (Gayathri et al., 2007). Their viability was determined by trypan blue exclusion 
test (Moldeus et al., 1978) and only cell viability greater than 95 %, as assessed by the 
trypan blue undergoes the MTT assay. The cells were then seeded onto 96-well flat 
bottom sterile tissue culture plates (Jet Biofil, China) at a density of 5 × 10
4 
cells/ml.  
All cell cultures were maintained at 37
 º
C in a humidiﬁed IR water-jacketed incubator 
(NuAire, Plymouth, MN, USA) with 5 % CO2 condition. 
 
 
Component Volume (µl) for 1 
reaction 
Final concentration 
TaqMan fast advanced Master Mix 5.0 µl 1X 
TaqMan Gene expression assay 0.5 µl 1X 
cDNA template 1.0 µl 20 ng 
Nuclease-free water 3.5 µl                   - 
Total volume per reaction 10.0 µl  
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3.8.2 MTT cell viability assay 
The effect of the extracts on cell viability of human PBMCs were determined by using 
MTT assay as described by Mosmann and Scudiero using MTT reagent (5 mg/ml) 
(Mosmann, 1983; Scudiero et al., 1988). Briefly, 100 µl of the isolated PBMCs 
suspension were cultured in 96-well flat bottom micro titer plates at 5 × 10
4 
cells/ml in 
RPMI medium containing 10 % (v/v) FBS and incubated at  37°C, 5 % CO2 and 90 % 
humidity incubator for 48 hr. The second day, the cells were treated with 20 µl of two 
fold serial dilution with final concentration (200, 100, 50, 25 and 12.5 µg/ml) of crude 
extracts and re-incubated at 37°C in humidified 5 % CO2 incubator for 24 hr. After 48 
hr, 10 µl of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
tetrazole) (Merck, Germany) was added into each well in the plates and again re-
incubated for four hr at  37°C in humidified 5 % CO2 incubator. The yellow MTT is 
reduced to purple formazan in the mitochondria of living cells (Mosmann, 1983). 
Approximately 80 µl of medium with MTT was removed from all wells and 100 µl of 
dimethyl sulfoxide (DMSO) (Fisher Scientific, UK) was added to each well to dissolve 
the insoluble purple formazan product into a colored solution. The absorbance of this 
colored solution measured at 595 nm using power wave x340 ELISA Reader (Bio-Tek 
Instruments, Inc., Winooski, VT, USA). The assay performed in triplicates in three 
independent experiments. The percentage of cell viability was calculated by the 
following formula and the results were expressed as mean ± SEM: 
% Cell viability = (Abs sample – Abs blank) / Abs blank X 100 
 
3.9 Profiling and Fractionation of crude extracts 
The ethanol crude extract  of both plants (10 gm) were subjected to column 
chromatography fractionation using a 3.0 x 50 cm glass columns (Kontes Scientific 
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Glassware, Vineland, NJ, USA) packed with silica gel G60, 70 - 230 mesh (Merck, 
Darmstadt, Germany) and connected with an EYEL-L1  type pump 
(Tokyo Rikakikai, Tokyo, Japan) . The crude extracts were eluted stepwise with 
gradient (25 ml each time of five different concentrations; 20, 40, 60, 80 and 100 %) of 
different solvents in the order of increasing polarity, started by less polarity toward the 
higher polarity. The solvents used were hexane, ethyl acetate, methanol, acetone, 
acetonitrile and water, all fractions collected in clean tubes and all eluents were then 
pooled to give six major fractions (Fraction 1–6) based on similarity of spots on thin 
layer chromatography (TLC) using aluminium foils pre-coated with silica gel 60 F254 
plate, 20x20 cm, 0.2 mm (Merck, Darmstadt, Germany). The solvents were evaporated 
under reduced pressure in centrifuge evaporator and freeze dryer (Awaad et al., 2008). 
The isolation of the compounds was monitored by TLC using mixtures of ethyl acetate 
and methanol. All fractions and the crude extract subjected to in vitro hepatoprotective 
cell line assay and those given positive result identified by high performance liquid 
chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) to 
determine the active constituents.  
 
3.10 In vitro hepatoprotective activity of plant crude extracts and isolated fractions 
3.10.1 Cell line and culture conditions 
The normal hepatic human cell line (WRL-68) obtained from American Type Culture 
Collection (ATCC) (appendix III). WRL-68 cells were cultured in Dulbecco’s modified 
eagle’s medium (DMEM) (Sigma-Aldrich, UK) supplemented with 10 % (v/v) FBS  (J 
R Scientific, Inc, USA) and 1 % (v/v) penicillin-streptomycin solution (Sigma-Aldrich, 
UK). WRL-68 cell lines were cultured at 37° C in humidified 5 % CO2 incubator, and 
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cells were split twice weekly using trypsin / EDTA (Sigma-Aldrich, UK). Cells from 
passage 20-25 were used for the experiment. 
 
3.10.2 Hydrogen peroxide treatment evaluation 
Hydrogen peroxide (H2O2) was added to WRL-68 cell line to induce cell oxidative 
damage in vitro. Approximately 100 µl of WRL-68 cell line suspension was seeded 
onto 96-well flat bottom sterile tissue culture plates at a density of 5 × 10
4 
cells/ml and 
incubated at 37°C, 5 % CO2 and 90 % humidity incubator for 24 hr. The second day, the 
cells were exposed to 10 µl of different freshly prepared H2O2 dilutions (Merck, 
Darmstadt, Germany) with final concentration (100, 200, 400, 600, 800 and 1000 µM) 
and re-incubated at 37°C in humidified 5 % CO2 incubator for 2 hr (Spitz et al., 1987). 
The effect of the H2O2 on cell viability was determined by MTT assay as described 
previously (Mosmann, 1983; Scudiero et al., 1988). The H2O2 concentration that can 
inhibit the WRL-68 cell viability to 40-50 % comparing with untreated cells was chosen 
for in vitro hepatoprotective activity experiment. 
 
3.10.3 In vitro hepatoprotective activity and cell viability test 
The MTT assay was used to assess cell damage by the H2O2 and cell viability protection 
by the crude extracts and isolated fractions as described by (Chen et al., 2006b; 
Weecharangsan et al., 2006)  with some modification.  Briefly, 100 µl of the WRL-68 
cell line suspension were seeded in 96-well flat bottom micro titer plates at 5 × 10
4 
cells/ml in DMEM medium containing 10 % (v/v) FBS and allowed to attach overnight. 
The second day, the cells were treated with 100 µg of various treatment doses according 
to (Table 3.6) and incubated at 37°C with 5 % CO2 for 2 hr. The treated cells were 
induced by 10 µl of freshly prepared 1000 µM H2O2 (this concentration obtained from 
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H2O2 treatment evaluation experiment) and re-incubated at 37°C for 2 hr. The 
hepatoprotective effect of plant extracts and isolated fractions were determined by cell 
viability using MTT assay as described previously (Mosmann, 1983; Scudiero et al., 
1988). Cell viability was calculated as a percentage compared to the untreated control 
and the H2O2 groups. The assay performed in triplicates and the percentage of cell 
viability was calculated as means ± SEM. 
 
 
Table 3.6 In vitro hepatoprotective activity of plant extracts and isolated fractions 
experimental design 
 
Group Name Oxidant agent  
(1000 µM H2O2)  
Treatment  
(100 µg/ml) 
Control (Normal 
cell group) 
No oxidant agent (10 µl 
medium) 
No treatment (10 µl solvent) 
H2O2 (Oxidative 
damage group) 
10 µl No treatment (10 µl solvent) 
O.  stamineus 10 µl 10 µl O.  Stamineus ethanol extract 
M.  citrifolia 10 µl 10 µl M.  citrifolia ethanol extract 
O.  stamineus F1 10 µl 10 µl O.  Stamineus fraction No. 1 
O.  stamineus F2 10 µl 10 µl O.  Stamineus fraction No. 2 
O.  stamineus F3 10 µl 10 µl O.  Stamineus fraction No. 3 
O.  stamineus F4 10 µl 10 µl O.  Stamineus fraction No. 4 
O.  stamineus F5 10 µl 10 µl O.  Stamineus fraction No. 5 
O.  stamineus F6 10 µl 10 µl O.  Stamineus fraction No. 6 
M.  citrifolia F1 10 µl 10 µl M.  citrifolia fraction No. 1 
M.  citrifolia F2 10 µl 10 µl M.  citrifolia fraction No. 2 
M.  citrifolia F3 10 µl 10 µl M.  citrifolia fraction No. 3 
M.  citrifolia F4 10 µl 10 µl M.  citrifolia fraction No. 4 
M.  citrifolia F5 10 µl 10 µl M.  citrifolia fraction No. 5 
M.  citrifolia F6 10 µl 10 µl M.  citrifolia fraction No. 6 
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3.11 In vitro antioxidant for cell line experiment  
The crude extracts of both O. stamineus and M. citrifolia and the fractions that prevent 
the oxidative damage in the in vitro hepatoprotective activity experiment (O. stamineus 
F3 and M. citrifolia F2) were used for antioxidant assay experiment. Approximately, 
1000 µl of the WRL-68 cell line suspension were seeded in 12-well flat bottom micro 
titer plates at 2 × 10
6 
cells/ml in DMEM medium containing 10 % (v/v) FBS and 
allowed to attach overnight. The second day, the cells were treated with 100 µg of 
various treatment doses in triplicate according to (Table 3.7) and incubated at 37°C with 
5 % CO2 for 2 hr. The treated cells were induced by 100 µl of freshly prepared 1000 µM 
H2O2 and re-incubated at for 2 hr. The H2O2-treated and -untreated cells after removing 
the medium, were harvested, washed twice with PBS and lysed in lysis buffer (25 
mmol/l Tris-HCl). WRL-68 cell lysates were prepared in a 0.5 ml cold phosphate buffer 
saline (PBS) (pH 7.4). All The cell debris was removed by centrifugation at 100 rpm for 
10 min at 4°C using refrigerated centrifuge Rotofix 32 (Hettich Zentrifugen, Germany). 
All samples were sonicated for 5 min with 10 sec rest after each min. The samples were 
kept at -20°C until used. The supernatant was used for the estimation of the following 
antioxidant using commercially available kits from (Cayman Chemical Company, 
USA): malondialdehyde (MDA) (Item No. 10009055), Catalase (Item No. 707002), 
superoxide dismutase (Item No. 706002) and glutathione peroxidase (Item No. 703102) 
activities. All assays performed according to the instruction manual of the manufacturer 
(appendix III). Protein concentration was determined by the Bradford method using 
bovine serum albumin as a standard (Bradford, 1976). 
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Table 3.7 In vitro antioxidant for cell line experimental design 
 
Group Name Oxidant agent  
(1000 µM H2O2)  
Treatment  
(100 µg/ml) 
Control (Normal 
cell group) 
No oxidant agent (100 µl 
medium) 
No treatment (100 µl solvent) 
H2O2 (Oxidative 
damage group) 
100 µl No treatment (100 µl solvent) 
O.  stamineus 100 µl 100 µl O.  Stamineus ethanol extract 
M.  citrifolia 100 µl 100 µl M.  citrifolia ethanol extract 
O.  stamineus F3 100 µl 100 µl O.  Stamineus fraction No. 1 
M.  citrifolia F2 100 µl 100 µl M.  citrifolia fraction No. 2 
Gallic acid 
(Standard drug) 
100 µl 100 µl M.  citrifolia fraction No. 3 
 
 
3.12 Identification of active constituents  
In this study liquid chromatography-mass spectrometry (LC-MS) was used for 
identification of phenolics and other active constituents in the fractions that give 
positive result with in vitro hepatoprotective activity assay i.e., O. stamineus fraction 3 
(F3) and M. citrifolia fraction 2 (F2). The identification and characterization of isolated 
compounds from active fractions were performed by comparing ultraviolet (UV) and 
mass spectrometry (MS) as described by (Lin et al., 2008; Masuda et al., 1992). The 
components of fractions such as phenolics give positive or negative ion mass spectra 
containing intense [M+H]
+
,[M-H]
-
 ions as well as fragment ions created after the 
cleavage of compound bonds. The method development and optimization were done at 
Cancer Research Initiatives Foundation (CARIF) laboratory (appendix I). 
 
64 
 
3.12.1 Sample preparation 
Samples of fraction (5 mg each) were dissolved in 5 ml of methanol, and sonicated for 
10 - 15 min. The contents filtered through a 0.45 µm syringe filter. The stock solutions 
were used for further dilutions and kept in fridge at 4°C prior to analysis. 
 
3.12.2 Instrumentation and parameter used 
Instrument details: Waters Ultra Performance Liquid Chromatography (Waters UPLC) 
Software used: Waters MassLynx 4.1 
Column specification: ACQUITY UPLC BEH C18 1.7µm, 2.1 x 50mm Column 
Detector: ACQUITY PDA Detector (ACQ-PDA) Version 1.40.1932 
The fractions were monitored at 280 nm, and UV spectra from 190 to 800 nm were 
recorded for peak characterization. Full scan mass spectra were measured between m/z 
150 and 1000 u in both positive and negative ion mode. 
Waters Synapt HDMS 
Electron spray ionization (ESI) 
Source (same for +ve and –ve mode): 
a) Capillary voltage: 2.7 kV 
b) Sampling cone: 40 
c) Extraction cone: 4.0 
d) Source temperature: 100° C 
e) Desolvation temperature: 350° C 
f) Cone gas flow: 30 L/h 
g) Desolvation gas flow: 700 L/h 
Company name: Cancer Research Initiatives Foundation (CARIF) 
Type & length of column: Reverse phase C-18; 2.1 x 50 mm; 1.7 µm particle size 
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Injection volume:  3 µL 
Flow rate: 0.5 ml/ min 
Positive and negative ions are analyzed in mass spectrometers. 
Solvent system: H2O + 0.1 % Formic acid/ acetonitrile (ACN) + 0.1 % Formic acid 
according to the gradient condition mentioned in (Table 3.8). 
 
Table 3.8 UPLC and LC-MS gradient conditions 
Time (min) H2O + 0.1 % F.A (%) ACN + 0.1 % F.A (%) 
0.00 100 0 
7.00 0 100 
10.00 0 100 
11.00 100 0 
15.00 100 0 
 
 
3.13 Antibacterial assay  
3.13.1 Microorganisms 
The following bacteria strains were used as test organisms: Staphylococcus aureus 
(ATCC 25923), Streptococcus agalactiae (laboratory isolate supplied from the Clinical 
Microbiology Laboratory / University of Malaya), Escherichia coli (ATCC 25922) and 
Klebsilla pneumonia (ATCC 700603). 
 
3.13.2 Disk diffusion method 
Antimicrobial susceptibility test of the isolated organisms was done by disc diffusion 
method using the Kirby-Bauer technique (Bauer et al., 1966) and according to the 
standards of the National Committee for Clinical technique Laboratory Standards 
(NCCLS, 2003). All tests were performed on Mueller-Hinton agar, the surface of media 
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was lightly and uniformly inoculated by cotton swab. Prior to inoculation, the swab 
stick was dipped into bacterial suspension having visually equivalent turbidity to 0.5 
McFarland standards (approximately 1.5 x 10
6
 CFU/ml). The swab stick was then took 
out and squeezed on the wall of the test tube to discard extra suspension. Sterile 6.0 mm 
diameter blank discs (Oxoid, Basingstokc, England) were used to load 50 µl of the plant 
extracts (equivalent to 5 mg/disc) dissolved in 5 % sterile DMSO for ethanol extracts 
and in sterile distilled water for aqueous extracts, then discs were allowed to dry. 
Amoxicillin 2 µg/disc, Gentamicin 30 µg/disc and Vancomycin 5 µg/disc were obtained 
from Oxoid Ltd (Oxoid, Basingstokc, England) were used as a positive control, whereas 
solvent loaded discs as negative control. The extracts, 5 % sterile DMSO, sterile 
distilled water impregnated discs  and the standard drug antibiotic discs were placed on 
Muller-Hinton agar and incubated at 35°C for 18-20 hours. On the next day, the 
diameters of inhibition zones in mm were recorded, the experiment was performed in 
triplicates and average diameter of zone of inhibition was calculated. 
 
3.13.3 Minimum inhibitory concentration (MIC) and Minimum bactericidal 
concentration (MBC) 
The Broth micro-dilution method was used to determine the MIC according to the 
National Committee for Clinical Laboratory Standards guidelines (NCCLS, 2003), this 
assay was done for the extracts that exhibited considerable activity against bacteria in 
the disk diffusion method (inhibition  one ≥ 8 mm). Using sterile round-bottom 96-well 
plates, twofold serial dilutions of extracts were prepared in the appropriate broth 
containing 5 % (v/v) DMSO. Briefly, each plant extract was issued to a serial dilution 
by using sterile Nutrient broth. The concentrations of plant extracts were 50, 25, 12.5, 
6.25, 3.13, 1.56, and 0.78 mg/ml. Approximately 10 μl of a bacterial cell suspension 
prepared in Nutrient broth, corresponding to 0.5 McFarland standards, was added to all 
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wells except those served as negative control. A generally recommended initial cell 
concentration is 5×10
5
 CFU/tube. Controls for bacterial growth without plant extracts 
were also included on each plate; plate was then incubated at 37°C for 18-20 h. The 
higher dilution of the plant’s extracts [i.e., lowest concentration] that produced no 
visible growth of the bacteria (no turbidity) when compared with the control wells were 
considered as the MIC of the extract. After that, the contents of all wells that showed no 
visible growth were cultured on nutrient agar and incubated further at 37°C overnight, 
the next day, the lowest concentration that showed no single bacterial colony on agar 
considered as the MBC.  
 
3.14 Statistical analysis  
The statistical significance was assessed using one-way analysis of variance (ANOVA) 
followed by Bonferroni’s or LSD multiple comparison test. All values were expressed 
as mean ± SEM and a value of p <0.05 was considered significant as compared to the 
respective control group using SPSS programme for windows version 18 (SPSS Inc. 
Chicago, IL, USA). 
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CHAPTER IV 
RESULTS 
 
4.1 Antioxidant activity 
O. stamineus exhibited high free radical scavenging activity towards DPPH and ABTS 
radicals (Figure 4.1 and Figure 4.2). DPPH data in (Table 4.1) showed that there is no 
significant difference between the IC50 of the ethanol extract of O. stamineus (21.4 ± 
0.104 µg/ml), and the IC50 of the synthetic antioxidant standard BHT (21.1 ± 0.031 
µg/ml). On the other hand, ethanolic extract of M. citrifolia does not have significant 
free radical scavenging activity with IC50 >25 µg/ml (Table 4.1). Moreover, O. 
stamineus exhibited high antioxidant activity as proven by FRAP. Data in (Table 4.1) 
showed that the FRAP result of O. stamineus is comparable to that of standard ascorbic 
acid as there is no statistically significant difference between them, while the M. 
citrifolia has very low FRAP activity. On the other hand, the total phenolic contents 
(TPC) in ethanolic extract of O. stamineus were 294.3± 0.051 mg (Gallic acid 
equivalents) per g of extracts (standard curve equation: y = 0.0013x + 0.0032, R² = 
0.987). At the same time, flavonoids were 171.4 ± 0.016 mg (Quercetin equivalents) per 
g of extracts (standard curve equation: y = 0.0040x + 0.0085, R² = 0.991), and a ratio 
flavonoids/phenolic of 0.58 (Figure 4.3 and Table 4.1).  The correlation between the 
TPC results and antioxidant activity represented by DPPH, FRAP and ABTS are 0.996, 
0.983 and 0.997 respectively (Figure 4.4).  Thus, phenolic compounds were the 
predominant antioxidant components in O. stamineus ethanol extracts, which lead to 
more potent radical scavenging effect and antioxidant activity.  
     
69 
 
Table 4.1 Crude extracts antioxidant activity, total phenolic and flavonoids of the investigated plants 
 
Plant extracts and standards 
DPPH  IC50   
(µg/ml) 
FRAP      
 (µmol Fe (II)/g) 
ABTS IC50 
(µg/ml)  
TPC value              
mg Gallic acid/g 
of extract 
Flavonoids           
mg Quercetin/g 
of extract 
Flavonoids/ 
Phenolic 
Ratio 
O. stamineus Ethanol Extract 21.4± 0.104
b
 1692.8± 85.09
c
 83.5± 0.285
c
 294.3± 0.051
b
 171.4± 0.016
b
 0.58 
M. citrifolia Ethanol Extract >25 280.6± 41.76
a
 >100 46.0 ± 0.013
a
 31.8± 0.023
a
 0.69 
BHT 21.1±0.031
b 988.8± 24.83
b
 69.7±0.470
b 
-------- --------
 
-------- 
Ascorbic acid 4.6±0.006
 a
 1987.4± 34.98
c
 24.5± 0.384
a
 -------- -------- -------- 
 
All results are represented the mean ± SEM of triplicates; a-c Means followed by the same letters are not significantly different, * P < 0.05. Both ascorbic acid and 
(BHT) butylated hydroxyltoluene used as standards. 
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Figure 4.1 Percentage of DPPH scavenging activity of O. Stamineus, M. citrifolia and 
standards, all serial dilution in µg/ml.   
 
 
 
Figure 4.2 Percentage of ABTS inhibitions of O. Stamineus, M. citrifolia and standards, 
all serial dilution in µg/ml.   
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Figure 4.3 Standard curve equations of TPC and flavonoids.  
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Figure 4.4 Correlation between TPC and antioxidant activity represented by DPPH, 
FRAP and ABTS 
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4.2 Acute toxicity  
All animals showed no mortality and did not manifest any significant signs of toxicity. 
There were no abnormal signs, behavioural changes, or body weight changes at any 
time of observation. There was no mortality up to 5 g/kg dose of both plants at the end 
of 14 days of observation. Histological examination of liver and kidney, revealed no 
significant changes between the different groups (Figure 4.5). Consequently, it is 
concluded that the crude extracts of O. stamineus and M. citrifolia are safe, even at 
these higher doses and have no toxicity and the oral lethal dose (LD50) is greater than 5 
g/kg body weight. 
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Figure 4.5 Histological sections of liver and kidney in acute toxicity test. Rats (1a and 
1b) treated with 5 ml/kg vehicle as control group. Rats (1c and 1d) treated with (5 g/kg 
(5 ml/kg) O. stamineus extract. Rats (1e and 1f) treated with 5 g/kg (5 ml/kg) M. 
citrifolia (H & E stain 20x). 
 
4.3 In vivo hepatoprotective activity of plant extracts  
4.3.1 Body, liver and spleen weight  
Before starting of treatment the rats weighed 200–250 gm and after two months animals 
of normal, O. stamineus HD, O. stamineus LD, M. citrifolia HD, M. citrifolia LD and 
Silymarin groups reached average body weights of 254.9, 232.7, 263.3, 244.5, 235.7 
1a 1b 
1f 
1d 
1e 
1c 
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and 257.0 gm respectively. However, TAA positive control group the average body 
weight was decreased to 202.0 gm but without a significant difference compared to the 
normal control group. There was no significant difference between the groups but long 
term taken of TAA led to significant increase of the liver weight compared to normal 
rats. Values of mean relative liver weight (LW/BW) percent, showed a significant 
difference between treated groups compared to TAA group (Table 4.2).  
 
4.3.2 Biochemical parameters  
Long term administration of TAA led to significant increase of biochemical markers 
ALT, AST, ALP, and Bilirubin level, while significantly decreased total protein and 
albumin compared to the normal control group, indicating acute hepatocytes damage. 
Treatment of animals with O. Stamineus, M. citrifolia extracts and Silymarin 
significantly reduced the level of liver function biomarker (ALT, AST, ALP and 
bilirubin), in addition significantly increased in total protein and albumin comparing 
with the TAA group. The toxic effect of TAA was controlled in the rats treated with 200 
mg/kg ethanolic extracts of both plants and that’s approved by restored of the levels of 
the liver biomarker.  At a dose of 100 mg/kg, in O. stamineus the effect was only 
marginal, whereas there was no significant difference for M. citrifolia (Table 4.3). The 
ethanol extracts of O. stamineus significantly restored the altered liver parameters and 
made it more resemble to that of standard drug Silymarin (50 mg/kg). Moreover, O. 
stamineus extract at 200 mg/kg (P<0.01) demonstrated the most potent effect in 
protecting rats against TAA-induced liver damage, as evidenced by the reduced  in all 
enzyme levels of AST, ALT and ALP and increased in total protein and albumin levels 
compared to the control. 
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Table 4.2 Effects of TAA, Silymarin O. stamineus and M. citrifolia ethanolic extracts intake on the body, liver and spleen weight of rats 
 
 
Animal Group 
Body weight (gm) 
(BW) 
Liver weight (gm) 
(LW) 
LW/BW    
(%) 
Spleen weight (g) 
(SW) 
SW/BW  
(%) 
Normal Control 254.9± 28.69 6.71± 0.64 2.71± 0.18 0.47± 0.08 0.18± 0.02 
TAA Control (hepatotoxic group) 202.0± 19.10 11.00 ± 1.11
*a
 5.43± 0.17
*a
 0.52± 0.07 0.26± 0.03 
O. stamineus HD 200mg/kg 232.7± 16.12 10.43 ± 0.69 4.50± 0.19
*b
 0.54± 0.04 0.23± 0.01 
O. stamineus LD 100mg/kg 263.3± 8.53 10.43 ± 0.72 3.94± 0.16
*c
 0.55± 0.03 0.21± 0.01 
M. citrifolia HD 200mg/kg 244.5 ± 15.84 10.67 ± 0.71 4.45 ± 0.37 0.47 ± 0.05 0.22 ± 0.02 
M. citrifolia LD 100mg/kg 235.7 ± 17.52 10.00 ± 0.87 4.27 ± 0.26
*b
 0.48 ± 0.05 0.23 ± 0.01 
Silymarin 50mg/kg (hepatoprotective group) 257.0± 21.97 7.71 ± 1.08 2.94± 0.13
*c
 0.53± 0.07 0.20± 0.01 
 
All values are expressed as mean ± S.E.M. Means with different superscripts are significantly different. a P < 0.05 versus Normal control group, b P < 0.05 versus TAA control 
group, and  c P < 0.01 versus TAA control group.  
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Table 4.3 Effect of TAA, Silymarin, O. stamineus and M. citrifolia ethanolic extracts intake on serum hepatic biomarker in TAA-induced liver 
cirrhosis in rats 
 
Animal Group 
ALT         
(IU/L) 
AST       
(IU/L) 
ALP      
(IU/L) 
Bilirubin 
(mg/dl) 
Total Protein 
(g/l) 
Albumin 
(g/l) 
Normal Control 64.9± 4.19 164.4± 10.74 109.6± 9.80 1.86± 0.14 74.3± 1.15 12.1± 0.51 
TAA Control (hepatotoxic group) 213.3± 25.98
*a
 372.6± 29.98
*a
 435.8 ± 29.78
*a
 8.7± 0.57
*a
 60.7± 0.97
*a
 8.3± 0.57
*a
 
O. stamineus HD 200mg/kg 95.7± 9.35
*c
 228.6± 14.10
*c
 289.0 ± 14.23
*c
 4.8± 0.59
*c
 68.0± 2.06
*c
 11.1± 0.63
*b
 
O. stamineus LD 100mg/kg 108.0± 11.15
*c
 253.4± 18.67
*c
 383.6± 20.89 6.4± 0.72
*b
 64.6± 1.29 9.3± 0.36 
M. citrifolia HD 200mg/kg 100.8± 10.09
*c
 248.8± 24.66
*b
 301.2 ± 9.81
*c
 4.7± 0.49
*c
 69.5± 1.23
*c
 11.3± 0.49
*c
 
M. citrifolia LD 100mg/kg 143.0± 17.95
*b
 273.1± 31.88
*b
 387.9± 25.20 6.7± 0.99 66.1± 2.58 10.4± 0.53 
Silymarin 50mg/kg (hepatoprotective group) 70.4± 5.60
*c
 171.6± 10.19
*c
 139.4 ± 9.54
*c
 3.0± 0.31
*c
 70.9± 0.91
*c
 11.7± 0.68
*c
 
 
All values are expressed as mean ± S.E.M. of eight rats in each group. Means with different superscripts are significantly different. a P < 0.05 versus Normal control group, b P < 
0.05 versus TAA control group, and  c P < 0.01 versus TAA control group.  ALT: alanine aminotransferase, AST: aspartate aminotransferase, and ALP: alkaline phosphatase. 
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4.3.3 Histopathology examination 
Histopathological examination of liver sections of the normal group showed regular 
cellular architecture with distinct hepatic cells, sinusoidal spaces and a central vein. The 
hepatocytes are polygonal cells with well preserved cytoplasm, nucleus with prominent 
nuclei. On the other hand, in the hepatotoxic positive control group histological 
examination showed loss of architecture, inflammation and congestion with cytoplasmic 
vacuolation, fatty change, sinusoidal dilatation, centrilobular necrosis, displayed 
bundles of collagen surrounding the lobules, which resulted in huge fibrous septa and 
distorted tissue architecture. In O. stamineus and M. citrifolia treated animals liver 
sections showed mild inflammation and mild necrosis of hepatocytes with mild 
cytoplasmic vacuolation, and mostly no visible changes observed. Histopathological 
examination also showed good recovery of thioacetamide-induced necrosis by ethanolic 
extracts as compared to Silymarin. Animals treated with the low dose showed 
regeneration of hepatocytes surrounded by septa of fibrous tissue with a significant 
increase in bile ductules, fat storing cells, and Kupffer cells. Animals treated with the 
higher dose of both plant extracts showed remarkable histological regeneration 
compared to those of the LD groups. They showed nearly ordinary patterns with an 
increase normal hepatocytes parenchyma and a reduced development of fibrous septa 
and lymphocyte infiltration. Results of the gross and histopathological examination are 
shown in the figures (Figure 4.6 and Figure 4.7). 
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Normal TAA control O. stamineus HD 200mg/kg O. stamineus LD 100mg/kg 
 
Figure 4.6 Effect of TAA and O. Stamineus ethanolic extracts on liver gross and histology in TAA -induced liver cirrhosis rats after two months treatments, (H & E 
stain 20x). 
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M. citrifolia HD 200mg/kg M. citrifolia LD 100mg/kg Silymarin  
 
Figure 4.7 Effect of Silymarin and M. citrifolia ethanolic extracts on liver gross and histology in TAA -induced liver cirrhosis rats after two 
months treatments, (H & E stain 20x). 
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4.4 In vivo antioxidant activity in liver tissue  
The ABTS which represents the total antioxidant capacity significantly increased in 
high dose treatment groups of both plants and silymarin, while decreased in TAA 
induced groups due to long term excretion of free radicals. In addition, catalase, SOD, 
and GPx are some of the components of intrinsic antioxidant defence system; it is 
responsible for dissemination of free radicals such as superoxide radicals. During 
oxidative stress the body uses its defence mechanism to minimize the process of lipid 
peroxidation by using these antioxidant enzymes, thus, the activity of those enzymes 
become higher in early stages of TAA induction, but when the insult continue for long 
period, the enzymes become depleted and unable to fight against free radicals, which 
means that in advance stages of peroxidation due to TAA the activity of catalase, SOD, 
and GPx declined as shown in (Table 4.4). While the levels of these enzymes persist 
high in treatment groups, because the antioxidant properties of plant extracts against 
TAA induced free radicals. On the other hand, long term administration of TAA led to 
significant increase of MDA level compared to the normal control group, indicating 
acute hepatocytes damage. Treatment of animals with O. stamineus, M. citrifolia 
extracts and silymarin significantly reduced the level of MDA and lipid peroxidation.  
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Table 4.4 Effect of TAA, Silymarin, O. stamineus and M. citrifolia ethanolic extracts intake on some in vivo antioxidant parameters in TAA-
induced liver cirrhosis in rats 
 
Group 
ABTS 
(mM Trolox) 
CAT             
(U/mg protein) 
SOD 
(U/mg protein) 
GPx              
(U/mg protein) 
MDA 
(nmol/ mg protein) 
Normal Control 5.5 ± 0.60 2785.24 ± 34.32 326.23 ± 7.14 144.53 ± 0.63 38.74 ± 2.61 
TAA Control 3.23 ± 0.28 2123.57 ± 244.87
*a
 226.3 ± 8.58
*a
 81.44 ± 0.58
*a
 107.14 ± 3.71
*a
 
O. stamineus HD 200mg/kg 7.87 ± 0.21
*c
 2682.56 ± 40.78 298.77 ± 1.17
*c
 125.51 ± 1.07
*c
 45.34 ± 3.52
*c
 
O. stamineus LD 100mg/kg 6.52 ± 0.56
*b
 2492.06 ± 105.29 285.8 ± 6.82
*c
 117.43 ± 0.58
*c
 72.6 ± 3.94
*c
 
M. citrifolia HD 200mg/kg 7.19 ± 1.14
*c
 2580.26 ± 56.01 270.47 ± 3.44
*c
 120.95 ± 0.41
*c
 54.35 ± 1.73
*c
 
M. citrifolia LD 100mg/kg 6.59 ± 0.98
*b
 2479.75 ± 105.09 264.73 ± 0.93
*b
 109.84 ± 1.13
*c
 78.85 ± 2.26
*c
 
Silymarin 50mg/kg 8.53 ± 0.13
*c
 2684.16 ± 75.89 309.9 ± 9.50
*c
 126.01 ± 0.65
*c
 40.34 ± 2.8
*c
 
All values are expressed as mean ± S.E.M. Means with different superscripts are significantly different. a P < 0.05 versus Normal control group, b P < 0.05 versus TAA control 
group, and  c P < 0.01 versus TAA control group.   
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4.5 Genes expression 
According to the NormFinder and geNorm algorithm, the endogenous reference genes 
that showed the lowest variability were HPRT-1 and Ppia. However, GAPDH and Act b 
were shown differentially expressed, therefore excluded from further analyses 
(appendix IV). The gene expression levels of the target genes in animal liver tissue 
samples were normalized using both HPRT-1 and Ppia endogenous reference genes. 
The expression levels of TGFβ1, TIMP1, MMP2, Coll α and those two endogenous 
reference genes were subsequently validated by RT-PCR measurements. According to 
standard curve (appendix IV) all genes showed that the efficiency were between 90-110 
% and the slope between (-3.1) and (-3.5) which are within the reference criteria to run 
the quantitative RT-PCR (Table 4.5). After data analysis of Ct values by Gen EX 
software and normalized to the reference genes HPRT-1 and Ppia, all measured mRNAs 
showed a significantly different expression between calibrator group (normal liver 
tissue) and TAA group (cirrhosis liver tissue). All four target genes were up-regulated, 
three of them (TGFβ1, MMP2 and Coll α) were significantly over expressed in 
comparison to the calibrator. In contrast, we have demonstrated down-regulation of 
those three target genes in the O. stamineus and M. citrifolia treated groups, furthermore 
the down-regulations were highly significant difference (P < 0.01); in  O. stamineus 
treated group, while non significant in M. citrifolia group. Moreover, observed no 
significant changes in TIMP-l gene expression between TAA-induced group, O. 
stamineus and M. citrifolia treatment groups, but significant up-regulation in TAA 
group in comparison to the calibrator (Figure 4.8). The expression of TGFβ1 in TAA 
group increased 1.45 ± 0.21, (P = 0.02647) fold compared with calibrator (normal rats), 
whereas in O. stamineus and M. citrifolia treated groups expression was 0.72 ± 0.27, (P 
= 0.00291) and 1.22 ± 0.33 fold lower compared with the expression in TAA group. 
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However, mRNA levels of MMP2 were over expressed in TAA group to 10.78 ± 0.54, 
(P = 0.000035) fold higher compared to the calibrator and expressed 2.61 ± 0.57, (P = 
0.00355) and 4.18 ± 0.56, (P = 0.03084) in O. stamineus and M. citrifolia treated groups 
respectively. The fold induction of Coll α, in TAA group compared with calibrator was 
16.10 ± 0.92, (P = 0.00092) fold, whereas 3.36 ± 0.49, (P = 0.00062) and 8.70 ± 0.56 
folds in O. stamineus and M. citrifolia treated rats respectively (Table 4.6). 
 
 
Table 4.5 Measured efficiency slope and R
2
 of target and endogenous reference genes 
using the Ct slope method with 5 concentrations points  
 
Genes TGFβ1 TIMP1 MMP2 Coll α HPRT1 Ppia 
Reference 
criteria 
Efficiency 
(%) 
98.056 99.408 108.376 95.351 97.78 92.679 90 – 110 
Slope -3.369 -3.336 -3.136 -3.439 -3.376 -3.511 (-3.1) - (-3.5) 
Y-inter 28.85 34.01 31.042 32.567 28.026 27.154 ---------- 
R
2
 0.993 0.989 0.991 0.99 0.995 0.998 
Not less than 
0.98 
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Figure 4.8 Relative gene expression levels (Fold change) of TAA, O. stamineus and M. 
citrifolia ethanolic extracts treatment in comparison to the calibrator in TAA-induced 
rat liver cirrhosis tissue. All values are expressed as mean ± SEM. Means with different superscripts 
are significantly different. aP < 0.05 versus Calibrator, bP <0 .05 versus TAA group, and cP < 0.01 versus 
TAA group. 
 
 
 
Table 4.6 Effect of TAA, O. stamineus and M. citrifolia ethanolic extracts intake on 
mRNA gene expression levels in TAA-induced rat liver cirrhosis tissue 
 
 
All values are expressed as mean fold changes of mRNA from 7 rats ± SEM. Statistical analysis of 
differences was performed by a two-tailed unpaired student’s t test. Means with different superscripts are 
significantly different. aP < 0.05 versus Calibrator, bP <0 .05 versus TAA group, and cP < 0.01 versus 
TAA group. 
 
Group TGFβ1 TIMP1 MMP2 Coll α 
Calibrator 1 1 1 1 
TAA 1.45 ± 0.2106
*a
 2.23 ± 0.4991
*a
 10.78 ± 0.5378
*a
 16.10 ± 0.9189
*a
 
M. citrifolia 1.22 ± 0.3335 2.98 ± 0.5639 4.18 ± 0.5588
*b
 8.70 ± 0.5589 
O. Stamineus 0.72 ± 0.2678
*c
 1.72 ± 0.3839 2.61 ± 0.5659
*c
 3.36 ± 0.4923
*c
 
*a
 
*a
 
*c
 
*a
 
*b
 
*c
 
*a
 
*c
 
    Calibrator 
    TAA 
    M. citrifolia 
    O. Stamineus 
 
 
1  
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4.6 Immunomodulatory effects on PBMCs  
Both ethanol extracts of O. stamineus and M. citrifolia significantly stimulated the 
proliferation of PBMCs in vitro in a dose-dependent manner, but the O. stamineus 
extract has remarkable activity on PBMCs proliferation. Results showed that the cell 
viability increased after treatment, it is clear that the extract is not potentially toxic to 
the immune cells and it is modulating the cellular immune response. In our experiment, 
after an incubation period of 24 hr, treatment with 200 µg/ml of O. stamineus and M. 
citrifolia ethanol extracts significantly increase the number of PBMCs with 242.53 
±4.33 % and 123.77 ± 1.62 % respectively, compared to the control 105 ± 1.30 % 
(Figure 4.9). On the other hand, there are no significant differences between 50, 25 and 
12.5 µg/ml ethanol extract of both plants and control. As shown in (Figure  4.10) only 
200 µg/ml of O. stamineus stimulated the PBMCs proliferation to more than double the 
amount of the initial PBMCs control numbers (242.53 ± 4.33 %), which may be of 
value in combination with other therapies in the treatment of immunodeficiency, cancer, 
infections and even autoimmune disorders.  
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Figure 4.9 Percentage of (PBMCs) cell viability of O. stamineus and M. citrifolia 
treated groups compared to control (untreated group). Each value represents the means ± 
S.E.M. of three independent experiments. Means with * symbol are significantly different versus control 
group, * p < 0.05. 
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Untreated cells (control group) Treated cells with 200 µg/ml O. stamineus Treated cells with 200 µg/ml M. citrifolia 
Figure 4.10 Photomicrographs of (PBMCs) cell viability of O. stamineus and M. citrifolia treated cells compared to control (untreated cells), 
(magnification 10x). 
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4.7 In vitro hepatoprotective activity of crude extracts and isolated fractions 
First, we performed cytotoxicity assay of H2O2 on WRL-68 cells to select the suitable 
concentration for hepatotoxicity induction experiments. Thus, we estimated the 
concentration of H2O2 that can inhibit WRL-68 cell viability to 40-50 % comparing 
with untreated cells. WRL-68 treated cells with H2O2 concentrations from 100 to 1000 
µM were tested for cell viability; the viable cells were quantified by MTT assay. After 2 
hr of treatment the cell number was reduced in a dose-dependent manner from 100 to 
1000 µM (Figure 4.11).  Cell line treated with H2O2 concentrations below 600 µM 
produced a slight decrease in cell viability and has no statistically difference comparing 
with untreated cells. However, concentrations between 600 – 1000 µM caused a 
significant decrease in viable cell number (Figure 4.11). Concentration of 1000 µM 
H2O2 significantly inhibited cell viability to 40.8 % and this concentration were chosen 
for further investigation.  Result of in vitro hepatoprotective activity experiment showed 
that oxidative stress by H2O2 resulted in a decrease of cell viability to 41.9 % after 2 h 
of treatment as compared with the control group. Nevertheless, cell viability was 
increased obviously when pre-incubated with plant extracts and its isolated fractions 
before treatment with H2O2. O. stamineus and M. citrifolia crude extracts showed the 
ability to inhibit cell death induced by H2O2. The activity of O. stamineus and M. 
citrifolia extracts were found to be significantly increased the cell viability to 81.1 % 
and 76.4 % respectively at the concentration 100 µg/ml. On the other hand, there was 
almost no variation in cell viability observed between the O. stamineus F3 (95.1 %) and 
M. citrifolia F2 (86.1 %) treated cells comparing to the control of untreated cells (Figure 
4.12). These results demonstrated that O. stamineus F3 and M. citrifolia F2 have 
prevented the WRL-68 death and normalized the oxidative damage generated by H2O2 
induction. Figure 4.13 showed morphology and the changes on WRL-68 cell viability 
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due to the effects of O. stamineus F3 and M. citrifolia F2 treatment on the H2O2 induced 
WRL-68 cells in comparison to the untreated cells.  
 
 
. 
 
                                                      
Figure 4.11 Effects of H2O2 on WRL-68 cell viability after exposure to varying 
concentrations of H2O2; data are expressed as mean ± SEM; *P < 0.05 
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Figure 4.12 Effect of O. stamineus, M. citrifolia extracts and its fractions pre-incubated 
treatment on WRL-68 cell viability before H2O2 exposure in comparison to control. All 
values are expressed as mean ± SEM; # P < 0.01 versus control group, * P < 0.01 
versus H2O2 group. 
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Untreated cells (normal control)  O. stamineus F3 treated cells after 
H2O2 exposure  
M. citrifolia F2 treated cells after 
H2O2 exposure 
H2O2 exposure cells (Oxidative 
damage group) 
Figure 4.13 Photomicrographs showing the effects of H2O2 and plant fractions treatment on (WRL-68) cell viability in comparison to the untreated 
cells, (magnification 10x). 
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4.8 In vitro antioxidant activity for cell line experiment  
O. stamineus and M. citrifolia and their fractions that prevent the oxidative damage in 
the in vitro hepatoprotective activity experiment namely; O. stamineus F3 and M. 
citrifolia F2 were used for antioxidant assay experiment. The oxidative stress was 
induced by exposing cells to 1000 µM H2O2 for 2 hr, while the protective effect of the 
plants and fractions reduced the oxidative stress. Cells were first pre-incubated with O. 
stamineus, M. citrifolia, O. stamineus F3, M. citrifolia F2 and Gallic acid as reference 
standard for 2 hr and then treated with 1000 µM H2O2. The antioxidant activities of 
O. stamineus, and M. citrifolia and their fractions were positively correlated with the 
improvement of the cell viability. It is obvious that H2O2 lead to the production of ROS, 
which in consequence reduced the antioxidant enzymes such as catalase and GPx. 
However, pre-treatment with plant extracts and the fractions decreased the free radical 
formation; therefore the antioxidant enzymes level became higher. Our results revealed 
that H2O2 exposed cells caused a statistically significant decrease in catalase and GPx 
activity to 1.81 and 10.88 U/mg protein respectively, whereas showed significantly 
increase in O. stamineus extract and O. stamineus F3. On the other hand, lipid 
peroxidation value, measured as MDA production, significantly increased in H2O2 
induce oxidative stress group 48.84 nmol/mg protein comparing to untreated cells 18.00 
nmol/mg protein. Whereas in cells pre-incubated with O. stamineus and O. stamineus 
F3 were significant prevent lipid peroxidation by reduction of MDA to 24.17 nmol/mg 
protein and 24.67 nmol/mg protein respectively, which are near to the MDA result of 
untreated cells 18.00 nmol/mg protein and even better then the gallic acid result (Table 
4.7). 
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Table 4.7 Effects of H2O2, O. stamineus, M. citrifolia extracts and its fractions on the 
antioxidant enzymes and MDA in H2O2 – induced WRL-68 cell line 
 
Group 
CAT              
(U/mg protein) 
SOD 
(U/mg protein) 
GPx         
(U/mg protein) 
MDA           
(nmol/mg protein) 
Normal Control 4.88 ± 0.025 9.91 ± 0.010 26.15 ± 0.200 18.00 ± 1.015 
H2O2 1.81 ± 0.030
*a
 9.65 ± 0.065 10.88 ± 0.185
*a
 48.84 ± 1.835
*a
 
O. stamineus  3.13 ± 0.115*c 9.00 ± 0.150 22.05 ± 0.195*c 24.17 ± 2.165*b 
M. citrifolia  2.53 ± 0.110
*c
 8.34 ± 0.025 19.01 ± 1.110
*b
 28.5 ± 6.830 
O. stamineus F3 3.07 ± 0.120
*c
 9.85 ± 0.020 21.27 ± 0.625
*c
 24.67 ± 5.000
*b
 
M. citrifolia F2 2.99 ± 0.040
*c
 8.91 ± 0.015 14.86 ± 2.295 27.00 ± 2.330 
Gallic acid 3.93 ± 0.040
*c
 9.27 ± 0.010 22.51 ± 0.540
*c
 26.33 ± 1.665 
 
Values are presented as means ± SEM,
 a 
P < 0.05 versus normal control group, 
b 
P < 
0.05 versus H2O2 group, and
 c 
P <0 .01 versus H2O2 group. 
 
 
 
4.9 Identification of active constituents of the active fractions 
We applied UPLC-DAD and LC-MS using positive and negative ionization mode in 
order to know the chemical structural information and to identify the phenolic 
constituents and other active compounds of O. stamineus F3 and M. citrifolia F2 
fractions. Approximately seven compounds (Table 4.8) were detected in O. stamineus 
F3 and four of them were characterized on the basis of the UV spectra and MS 
fragmentation patterns in comparison with literature or by searching the dictionary of 
natural products on DVD, Version 20:2 (2011) (CRC Press, Taylor & Francis Group, 
London, UK). In addition, three active compounds were detected in M. citrifolia F2 and 
two of them were identified. Typical HPLC-TOF/MS peaks and UV diode array 
chromatograms of the O. stamineus F3 and M. citrifolia F2 fractions are shown in 
(Figure  4.14 and Figure  4.19) respectively. Tables 4.8 and 4.9 showed all peaks 
detected with their retention time, UV max, observed m/z and the m/z of fragment ions. 
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The O. stamineus F3 compounds include ponkanetin at m/z  373.1287 (Figure 4.15), 
eupatorin at m/z 345.0950 (Figure 4.16), TMF (3-hydroxy-5, 7, 3, 4-tetramethoxy 
flavone) at m/z 359.1123 (Figure 4.17) and salvigenin at m/z  329.1025 (Figure 4.18), 
while the compounds of M. citrifolia F2 comprise scopoletin at m/z  193.0498 (Figure 
4.20) and P- coumaric acid at m/z  163.0390 (Figure 4.21). 
 
 
. 
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Figure 4.14 HPLC-TOF/MS and UV diode array chromatograms of  O. stamineus fraction 3 (F3); (A) Diode array detection UV spectra at 280 nm, (B) 
Diode array detection UV spectra at range between 190 and 800 nm, (C) TOF MS peaks in positive mode ionization 
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Figure 4.15 Mass spectrum (TOF MS ES+), chemical structure and UV max spectra of ponkanetin (peak No. 1) identified in O. stamineus F3  
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Figure 4.16 Mass spectrum (TOF MS ES+), chemical structure and UV max spectra of eupatorin (peak No. 2) identified in O. stamineus F3 
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Figure 4.17 Mass spectrum (TOF MS ES+), chemical structure and UV max spectra of TMF (3-hydroxy-5, 7, 3, 4-tetramethoxy flavone) (peak No. 4) 
identified in O. stamineus F3 
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Figure 4.18 Mass spectrum (TOF MS ES+), chemical structure and UV max spectra of salvigenin (peak No. 5) identified in O. stamineus F3 
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Table 4.8 Identification of phenolic compounds in O. stamineus F3 by UPLC-DAD and LC-MS data using positive ionization mode 
 
Peak 
No. 
RT 
 (min) 
UV 
ƛ max (nm) 
Suggested 
formula 
Observed 
m/z 
m/z of fragment ions 
observed 
Tentative identification M.W.                
(g/mol) 
1 3.34 215, 331 C20H21O7 373 411, 767, 181, 198, 315, 358 Ponkanetin  372.37 
2 3.43 214, 342 C18H17O7 345 367, 711, 184, 211, 330 Eupatorin  344.33 
3 3.64 217, 321 C19H19O6 343 365, 381, 707, 176,  282, 328 Unknown  -------- 
4 3.85 217, 340 C19H19O7 359 381, 593, 609, 171, 191, 347 TMF (3-hydroxy-5,7,3, 4-
tetramethoxy flavone)  
358.11 
5 4.19 217, 331 C18H17O6 329 351, 437, 453, 715, 119 Salvigenin  328.32 
6 4.67 192, 226 C35H43N2O13 699 694, 677, 715, 295, 313, 555, 267 Unknown -------- 
7 7.26 202, 234 C36H45O9 621 413, 149, 279 Unknown -------- 
 
RT: Retention Time, M.W.: Molecular weight 
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Figure 4.19 HPLC-TOF/MS and UV diode array chromatograms of M. citrifolia fraction 2 (F2); (A) Diode array detection UV spectra at 280 nm, (B) 
Diode array detection UV spectra at range between 190 and 800 nm, (C) TOF MS peaks in positive mode ionization 
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Figure 4.20 Mass spectrum (TOF MS ES+), chemical structure and UV max spectra of scopoletin (peak No. 1) identified in M. citrifolia F2 
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Figure 4.21 Mass spectrum (TOF MS ES-), chemical structure and UV max spectra of P-coumaric acid (peak No. 2) identified in M. citrifolia F2 
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Table 4.9 Identification of phenolic compounds in M. citrifolia F2 by UPLC-DAD and LC-MS data using positive and negative ionization mode 
 
Peak 
No. 
Mode RT 
 (min) 
UV 
ƛ max (nm) 
formula Observed 
m/z 
m/z of fragment ions 
observed 
Tentative 
identification 
M.W.                
(g/mol) 
1 +ve 1.94 204 C10H9O4 193 133, 273, 371, 399, 517 Scopoletin 192.16 
2 + ve 2.17 202 C14H23N6O5 355 371, 161, 285, 301, 463, 527, 603 Unknown -------- 
3 - ve 2.55 202, 219 C9H7O3 163 327, 493, 515, 655 P- Coumaric acid 164.16 
 
RT: Retention Time, M.W.: Molecular weight, (+ve) positive ionization mode, (−ve) negative ionization mode,  
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4.10 Antibacterial activity 
The antibacterial activity results of the investigated extracts are shown in (Table 4.10). 
Among the investigated extracts, the aqueous extract of O. stamineus showed 
significant activity against Staphylococcus aureus and Streptococcus agalactiae, with 
inhibition zones 10.5 and 8.1 mm, respectively, while there were no activities against 
gram negative bacteria (Escherichia coli and Klebsilla pneumonia). Moreover, it was 
found that aqueous extract has minimum inhibitory concentration (MIC) value of 1.56 
mg/ml, while the minimum bactericidal concentration (MBC) was 3.13 mg/ml against 
Staphylococcus aureus. On the other hand, the same aqueous extract has only moderate 
activity against Streptococcus agalactiae, with a MIC value of 3.13 mg/ml and MBC 
value of 6.25 mg/ml (Table 4.11).  
In addition, the ethanol crude extract of O. stamineus exhibited a weak antibacterial 
activity against Gram-positive bacteria (Staphylococcus aureus and Streptococcus 
agalactiae) with inhibition zones of 6.8 mm and 6.5 mm, respectively. The aqueous and 
ethanol crude extracts of M. citrifolia has no antibacterial activity against both gram 
positive and negative bacteria (Table 4.10). 
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Table 4.10 Antibacterial activity of O. stamineus and M. citrifolia extracts in disk 
diffusion method 
 
Plants and 
Control 
Extracts Average Inhibition Zone Diameter (mm) 
S. aureus S. agalactiae E. coli K. pneumonia 
O.  stamineus Ethanolic 6.8±0.09 6.5±0.09 ----- ----- 
Aqueous 10.5±0.20 8.1±0.07 ----- ----- 
M.  citrifolia Ethanolic ----- ----- ----- ----- 
 Aqueous ----- ----- ----- ----- 
Amoxicillin         
2 µg/disc 
 NT 13.1±0.15 NT NT 
Gentamicin        
30 µg/disc 
 NT NT 22.5 ± 0.29 21.5 ± 0.26 
Vancomycin         
5 µg/disc 
 
13.0 ± 0.12 NT NT NT 
NT, not tested; ___, no inhibition; Inhibition zones including the diameter of the paper disc (6 mm); Values 
are represented the mean inhibition zone (mm) ± SEM of triplicates. S. aureus, Staphylococcus aureus; S. 
agalactiae, Streptococcus agalactiae; E. coli, Escherichia coli; K. pneumonia, Klebsilla  pneumonia. 
 
 
Table 4.11 Minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) of the investigated extracts 
 
Plants  Extracts 
S. aureus S. agalactiae 
MIC 
(mg/ml) 
MBC  
(mg/ml) 
MIC 
(mg/ml) 
MBC  
(mg/ml) 
O.  stamineus Ethanolic NT NT NT NT 
Aqueous 1.56 3.13 3.13 6.25 
M.  citrifolia Ethanolic NT NT NT NT 
Aqueous NT NT NT NT 
MIC, Minimum Inhibitory Concentrations; MBC, Minimum Bactericidal Concentrations; NT, not 
tested (because the inhibition zone less than 8 mm or there are no antibacterial activity) 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
 
5.1 Liver cirrhosis mechanism and hepatoprotective activity of medicinal plants 
Hepatic cirrhosis is a wound healing process characterized by excessive accumulation 
of ECM especially collagen I in response to severe liver damage that occurs in many 
patients with chronic liver injury of any etiology and associated with inflammation and 
cell death with the tendency to progress into sclerosis. Toxic injury occurs in the liver 
more often than that in any other organ. When a drug is used widely, drug-induced liver 
injury has become a serious health problem. Thus research on the mechanism of drug-
induced liver injury is very useful in therapy and prevention of drug-induced liver injury 
(Xin & Cai-qin, 2008). Liver cirrhosis represents the end-stage process of liver fibrotic 
degeneration of the most chronic liver diseases. Complex cellular and molecular 
mechanisms resulting from chronic activation of tissue repair mechanism following 
tissue injury have been characterized. The fibrosis process initiated upon liver tissue 
injury occurred, followed by the inflammatory reaction with activation of Kupffer cells 
and stellate cells, which in turn leading to increased expression of pro-inflammatory and 
pro-fibrotic cytokines and the recruitment and activation of fibroblast responsible for 
increased production of ECM proteins (Flier et al., 1993). Activation of HSC is 
regulated by several soluble factors, including cytokines such as TGF-β1 and IL- 6 and 
products of oxidative stress as well as by extensive changes in composition and 
organization of ECM components (Gressner, 1991; Stalnikowitz & Weissbrod, 2003). 
The production of ECM protein certainly represents the most typical function of 
activated HSC. In addition, along the progression of the fibrotic process, qualitative and 
quantitative changes in ECM are also favoured by the fact that HSC express MMP 
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which lead to disruption of normal matrix. As scarring progresses from bridging fibrosis 
to the formation of complete nodules it results in architectural distortion and ultimately 
liver cirrhosis. 
On the other hand, many liver diseases are accompanied by unbalanced increase of ROS 
and related products of lipid peroxidation resulting from oxidative stress, which 
represent one aspect of a very complex series of events able to affect the liver cell 
structure and function. Moreover, in alcohol intoxication, viral hepatitis infection and 
metabolic disorders, ROS are now increasingly recognized to have significant role in 
both initiation and sustaining of liver fibrosis. During the development of fibrosis, 
kupffer cells and HSC are the actual key-players in such chronic disease process; exert a 
series of effects through the enhancement of the intracellular and extracellular levels of 
oxidants (Poli, 2000). Oxidative stress is essentially a consequence of a necrotic event, 
but not withstanding it, ROS produced by activated macrophages as well as reactive 
aldehydes stemming from membrane lipid peroxidation can stimulate the progression of 
collagen deposition in the inflamed tissue or organ. Production of ROS may be cause 
and consequence of cellular damage. For instance, many hepato-toxins lead to increased 
concentrations of ROS that cannot be handled in a normal way by the protective 
machinery of the cells (Marí et al., 2001). Excessive production of ROS results in lipid 
peroxidation leading to an increase in highly reactive aldehydic end products, altered 
signal transduction, modulation of gene expression, alteration of the redox state 
including decrease of glutathione levels, and induction of apoptosis and necrosis 
(Dalton et al., 1999). 
Based on understanding of the cellular and molecular basis of hepatofibrogenesis, 
hepatoprotective agents can be categorized as follows; agents for scavenging of free 
radicals and reducing oxidative stress, agents for cytoprotection and reduction of 
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inflammation and cell death, agents for inhibition of HSC activation and agents for 
fibrolysis and promotion of matrix degradation.  These strategies include the curing of 
primary disease to prevent injury; reducing inflammation; down-regulating stellate cell 
activation directly or by neutralizing proliferative, fibrogenic, contractile, and/or pro-
inflammatory responses of stellate cells; stimulating apoptosis of stellate cells; or 
increasing the degradation of scar matrix. Reducing oxidative stress is another type of 
intervention and silymarin (our reference drug) are very good candidates in this area (Li 
& Friedman, 1999). Even traditional drugs such as pentoxifylline (Windmeier & 
Gressner, 1997), as well-known phosphodiesterase inhibitor, were unexpectedly found 
to block HSC activation by interfering with the oxidative stress cascade suggesting new 
mechanisms for their anti-fibrotic activity. 
Popularity of herbal remedies is increasing worldwide and at least one quarter of 
patients with liver diseases use medicinal plants for the prevention and treatment 
of liver diseases. More efforts need to be directed towards methodological scientific 
evaluation for their safety and efficacy by subjecting to vigorous pre-clinical studies 
followed by clinical trials to scientifically prove their traditional uses on evidence-based 
findings (Stickel & Schuppan, 2007). Recently, some researches has confirmed the 
efficacy of several plants as hepatoprotective agents and evaluated their mechanisms of 
action. Silybum marianum (milk thistle) has been shown to have clinical applications in 
the treatment of liver cirrhosis via its antioxidative, antifibrotic, anti-inflammatory, 
immune-modulating, and liver regenerating effects. Picrorhiza kurroa, appears to have 
similar applications and mechanisms of action (Luper, 1998). In addition Curcuma 
longa , Camellia sinensis (green tea), and Glycyrrhiza glabra have been approved to 
exhibit hepatoprotective effects (Luper, 1999). Using different experimental models 
some other plant extracts were evaluated for their hepatoprotective activity such as 
Andrographis lineate, Azadirachta indica, Cassia fistula, Cleome viscose, Polygala 
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arvensis, Pterocarpus santalinus, Solanum nigrum, and Wedelia calendulacea (Bhawna 
& Kumar, 2009).  
5.2 Antioxidant properties of crude extracts 
O. stamineus ethanol extract exhibited high antioxidant activity, as proven by FRAP 
result and its scavenging activity towards ABTS and DPPH radicals, while ethanol 
extract of M. citrifolia were found to have weaker antioxidant properties. The antioxidant 
activity was expressed as IC50; it is the measure of concentration in μg/ml of extract that 
inhibits 50 % of DPPH radicals. The DPPH IC50 of O. stamineus was found to be 
21.4±0.104 μg/ml, which is almost the same as that of the standard BHT 21.1±0.031 
μg/ml. In the same study as shown in (Table 4.1) the FRAP result of O. stamineus 
(1692.8± 85.09 µmol Fe (II)/g) was significantly much higher than that of BHT (988.8± 
24.83 µmol Fe (II)/g) but a little lower than ascorbic acid (1987.4± 34.98 µmol Fe 
(II)/g) and there is no significant difference between them. In addition, correlation 
analysis between the antioxidant properties and total phenolic contents of extracts 
indicated that there was a linear relationship between antioxidant potency, free radical-
scavenging ability and the content of phenolic compounds of plant extracts (Figure 4.4). 
The calculated coefficients of correlations between antioxidant activity, scavenging 
effects on radicals and contents of phenolic compounds are shown in (Figure 4.4). 
Therefore, the high antioxidant activity of O. stamineus which led to more potent 
radical scavenging effects is certainly associated with the high content of phenolic and 
flavonoids components. The total phenolic contents of O. stamineus and M. citrifolia 
are in accordance with the DPPH, ABTS and FRAP results.  
The results of this study are consistent with the results published by Yam et al. (2007), 
who reported that water extract of O. stamineus has antioxidant and free radical 
scavenging properties. O. stamineus has been reported to possess antioxidant activity. 
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Furthermore, the plant exhibited significant radical-scavenging activity probably due to 
the higher concentration of caffeic acid derivatives, especially rosmarinic acid 
(Akowuah et al., 2005a; Ho et al., 2010). Furthermore, Akowuah found that O. 
stamineus exhibited antioxidative potency greater than a synthetic antioxidant BHA and 
almost equal to that of pure quercetin (Akowuah et al., 2005b). Rosmarinic acid and 
caffeic acid derivatives have been reported as predominant in O. stamineus extracts, 
which represent 67% of total identified phenolics (Sumaryono et al., 1991). A 
quantitative HPLC analysis for O. stamineus ethanol extracts showed that the 
rosmarinic acid concentration ranged between 0.117 and 0.091 mg/ml, depending on 
ethanol concentration (Olah et al., 2003). In another study the antioxidant activity of 
rosmarinic acid was greater than that of Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-
2-carboxylic acid) (Lu & Yeap Foo, 2002). Moreover, rosmarinic acid was reported to 
have a number of biological activities in vitro, such as anti-carcinogenic, antioxidant, 
antibacterial, and anti-inﬂammatory properties (Huang & Zheng, 2006). This plant 
could represent a potent source for antioxidant agent, which provides prophylaxis 
against many diseases like arteriosclerosis, heart diseases, and cancers. According to 
Sumaryono et al. (1991).  
The antioxidant capabilities of phenolic compounds are important for the human body 
to destroy the free radicals that exist in our body. Many of the polyphenols such as 
flavonoids have been identified as powerful antioxidants; moreover, play a significant 
role in the treatment of many diseases, including liver cirrhosis (Hollman & Ilja, 2000). 
In addition to that, a study by Madani et al. (2008) suggested that the hepatoprotective 
effect of Silybum marianum and Cichorium intybus extracts were attributed to the 
presence of flavonoids and their antioxidant effects.   
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5.3 In vivo hepatoprotective and antioxidant activities of plant extracts  
Thioacetamide is a known hepatotoxic, which produces hepatic necrosis in high doses 
by producing free radicals during TAA metabolism resulting in oxidative stress 
mediated acute hepatitis and induces apoptosis of hepatocytes in the liver (Sun et al., 
2000). In the in vivo hepatoprotective experiment, TAA model was used as 
hepatotoxicants to induce liver cirrhosis. It has been reported that long term taken of 
TAA induced cirrhosis in rats; on account of this, it is proven that TAA through 
cytochrome p-450 pathway is converted into a highly toxic metabolite N-acetyl-p-
benzoquinone imine (NAPBI) (Fontana et al., 1996). Meanwhile NAPBI is 
accompanied with glutathione and excreted in the urine as a conjugates. The acute 
hepatic necrosis induced by TAA, which activates cytochrome p450 and produces a 
highly reactive NAPBI that, by the way, combines with sulpha-hydryl groups of 
proteins and causes a rapid reduction of intracellular glutathione (Fontana et al., 1996). 
In addition, TAA promotes oxidative stress, both by increased formation of ROS and by 
depletion of oxidative defences in the cell. Furthermore, liver cells from TAA-treated 
animals are more susceptible to the cytotoxic effects of TNF-α and other cytokines than 
cells from normal animals. Mitochondria play a critical role in the apoptotic response, 
and alterations in mitochondrial function after chronic TAA treatment may contribute to 
enhanced cell death by apoptosis or necrosis (Hoek & Pastorino, 2002). Therefore, 
increases the oxygen free radical causing an oxidative stress and initiates apoptosis; 
consequently, the elevated liver enzymes (ALT, AST) are an indicator of cellular liver 
necrosis (Fontana et al., 1996). In addition, TAA interferes with the movement of RNA 
from the nucleus to the cytoplasm which may cause membrane injury resulting in a rise 
in serum liver markers (Saraswat et al., 1996). TAA is responsible for many changes 
occur for hepatocytes such as an increase in nuclear volume and enlargement of 
nucleoli,  cell permeability changes, rise in intracellular concentration of Ca++, and 
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effects on mitochondrial activity, which leads to cell death (Ahmad et al., 2002). On the 
other hand, the preclinical studies using different hepatotoxic substances showed that 
silymarin has multiple actions as a hepatoprotective agent. The antioxidant property, 
inhibition of the transformation of stellate hepatocytes into myofibroblasts, stimulation 
of protein synthesis, the anti-inflammatory and antifibrotic actions considered as most 
important leading to cell-regenerating (Ghosh et al., 2010; Kosina et al., 2002). 
The plasma concentration of ALT, AST, ALP, bilirubin, albumin and total protein 
determines the functionality and cellular integrity of the liver (Gowda et al., 2009). 
ALT and AST are biomarkers of the hepatocytes. Under pathological conditions of the 
liver including, cirrhosis, adverse effects of some drugs (e.g., TAA, paracetamol), there 
is a leak of these enzymes in to the plasma, thus raising their activity (Nyblom et al., 
2004). ALT is specific for the liver but AST is also found in other tissues including the 
red blood cells, the cardiac and the skeletal muscle. ALP is located in the biliary duct of 
the liver (Nyblom et al., 2006). Obstruction of this duct increases the level of the 
enzyme in the plasma. Albumin and globulin constitutes the total plasma proteins and 
are in ratio 2:1. Thus, albumin constitutes the major component of the Total Plasma 
protein. It is synthesized in the liver and therefore a diagnostic tool for the 
determination of liver functionality. It has a half life of 120 days and its level is lowered 
in chronic liver disease such as cirrhosis and in poor diet or states of impaired protein 
catabolism. Bilirubin is a catabolic intermediate of haem. High concentration of this 
molecule results in jaundice. However, the liver plays an important role in mopping 
bilirubin from the plasma. In this study TAA administration for eight weeks led to 
induced liver fibrosis, which has been proven by the significantly difference of 
biochemical markers between the TAA control and normal control groups. Thus, serum 
levels of liver function parameters like ALT, AST, bilirubin, alkaline phosphatase are 
elevated. The mechanism of liver fibrosis is not fully understood, but no doubt that 
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oxidative stress and ROS play an important role in pathological changes in the liver. At 
the same time, the hepatoprotective effect exhibited by O. stamineus and M. citrifolia at 
high dose 200 mg/kg was comparable to silymarin at dose 50 mg/kg in TAA-induced 
liver injury rats. Treatment with the ethanolic extracts of O. stamineus and M. citrifolia 
(200 mg/kg) has accelerated the return of the altered levels of liver function enzyme to 
the near normal profile. The abnormal reconstruction of the lobular architecture, the 
appearance of widespread fibrosis; in addition, nodular lesions of the hepatic 
parenchyma are the main characteristics of liver cirrhosis (Li & Crawford, 2004). Our 
histological findings prove that the ethanol extracts of O. stamineus and M. citrifolia 
affected the recovery of liver structure in TAA-induced liver cirrhosis rats. Indeed there 
was Remarkable reduction in fibrosis extent and a decrease of stellate infiltration in rats 
treated with plant extract compared to control TAA group. Histological studies 
confirmed the hepatoprotective effect of O. stamineus and M. citrifolia ethanolic 
extract. TAA treated rat liver sections showed fatty degeneration of hepatocytes and 
necrosis of cells. The O. stamineus extract treatment (200 mg/kg) almost normalized 
these effects in the histo-architecture of liver with much better than that of M. citrifolia 
(200 mg/kg). Furthermore, the severe fatty changes in the livers of rats caused by TAA 
were treated in the HD treatment of both plant groups. Therefore, the ethanol extracts of 
both O. stamineus and M. citrifolia could be promising hepatoprotective agents against 
thioacetamide induced liver damage in rats. The high dose (200 mg/kg) of O. stamineus 
and M. citrifolia improve the cellular integrity and functionality of the liver as 
demonstrated by the significantly decrease in the level of ALT, AST, ALP and bilirubin 
concentrations, moreover increase in albumin and total protein. 
Furthermore, the in vivo antioxidant activity investigated the effect of the plant extracts 
on SOD, CAT, GPx and MDA concentrations in rats liver homogenate and it was 
demonstrated that, liver damage is associated with significant increases of tissue lipid 
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peroxidation expressed as MDA level, which caused by oxidative stress and depletion in 
the tissue GSH levels. In addition, the extent of oxidative stress was demonstrated to be 
directly correlated with the amount of ALT detectable in the blood (De Maria et al., 
1996). SOD, CAT and GPx are components of the intrinsic antioxidant defence system, 
which is responsible for dissemination of superoxide radicals and other free radicals, 
during oxidative stress the body uses its defence mechanism to minimize the process of 
lipid peroxidation by using the antioxidant enzymes. Thus, the activity of these enzymes 
become higher in early stages of insult, but if the insult continue, the enzymes become 
depleted as shown in (Table 4.4) and unable to scavenge the free radicals, which means 
that in advance stages of peroxidation the activity of enzymes declined (Chin et al., 
2008a). However, in the O. stamineus and M. citrifolia treatment groups showed 
significant increase in these endogenous enzymes activities. In the current study reduced 
lipid peroxidation was revealed by a significant decrease in MDA level in groups 
treated with ethanol extracts of both plants. The results of the hepatoprotective effects of 
both extracts can be attributed to the presence of high content of phenolic and flavonoid 
compounds and their antioxidant effects besides the free radical scavenging property.  
Likewise, the hepatoprotective activity of the extracts could be due to neutralization of 
the toxic compounds produced by converting TAA to a highly toxic metabolite during 
cytochrome P-450 pathway as mentioned above. On account of this, O. stamineus 
extract has been reported recently to affect cytochrome P-450 enzyme system through 
its inhibition. Consequently, the toxic metabolite of TAA is affected by the O. 
stamineus extract that might lead to reduce the progress of liver necrosis (Hanapi et al., 
2010). The high antioxidant activity of O. stamineus is certainly associated with the 
high content of phenolic components. Furthermore, antioxidants from the herbal 
medicine were recently found to act as hepatoprotective in different animal models 
(Shimizu et al., 1999). It has been reported that the antioxidant defence system in the 
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liver of mice is activated after exposure to oxidative stress, but after prolonged time of 
exposure it causes failure of the antioxidant defence system resulting in initiation of 
liver injury (Santra et al., 2000). 
Taken together these findings, suggest that the ethanol extracts of O. stamineus and M. 
citrifolia exhibit hepatoprotective effect which was demonstrated by a significant decrease 
in the liver biomarker level in TAA-induced rat liver cirrhosis. Moreover, the plant extracts 
enhanced the activities of antioxidant enzymes (SOD, CAT and GPx) against the TAA-
induced hepatotoxicity in these animals, suggesting that the reduction of oxidative stress in 
this scenario likely plays a role in the mechanism of its hepatoprotective effects. In 
agreement with our result, the bilirubin lowering potential of O. stamineus was 
evaluated by Faizul et al (2009)  in jaundiced rats. Treatment of these rats with aqueous 
extract of O. stamineus for three days reduced the bilirubin level significantly to the 
normal value. Whereas lower dose (50 mg/kg body weight) resulted in the reduction in 
bilirubin level nearly half when compared to the control. Therefore, O. stamineus 
aqueous extract can be used to reduce bilirubin concentration to a normal level. 
Furthermore, recent study evaluated the protective effects of M. citrifolia fruit juice on 
acute liver injury induced by carbon tetrachloride (CCl4) in female SD rats. They found 
that M. citrifolia juice is effective in protecting the liver from extrinsic toxin exposure 
(Wang et al., 2008). However, caution should be taken when animal studies are 
extrapolated to human, because there are significant qualitative and quantitative 
differences in the major drug metabolism enzyme cytochrome P-450 mixed function 
mono-oxygenases. Some subfamilies of P-450 in human versus animal catalyze 
xenobiotics biotransformation differently leading to unlike metabolites and it need 
further clinical evaluation (Guengerich, 1997). 
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5.4 Genes expression 
Gene expression represents a key role in the liver tissue response to pro-inflammatory 
and pro-fibrotic stimuli, which expressed by an intense transcriptional activation of a 
wide variety of genes, in different way involved in tissue repair. Oxidative stress and 
lipid peroxidation derived aldehydes, appears able to activate AP-1, a transcription 
factor which has been demonstrated to be essential for optimal transcription of many 
genes, whose some of primary interest in liver fibrosis, like TGF–β1, collagen type I 
and MMP2 (Armendariz-Borunda et al., 1994; Feinberg et al., 2000). In the current 
study all four target genes i.e. TGFβ1, MMP2, TIMP-l and Coll α were significantly up-
regulated in TAA-induced liver cirrhosis group compared to the normal group, whereas 
three of them namely; TGFβ1, MMP2, and Coll α; were highly significant (P < 0.01) 
down-regulated in O. stamineus treatment group. At the same time the fourth target 
gene TIMP-l showed no significant difference in mRNA expression between plants 
extract treatment groups and TAA group (Figure 4.8). In normal rat liver, TGF–β1 is 
mainly produced by Kupffer cells with some contribution by endothelial cells. 
However, in the drug-induced fibrotic rat liver, evidence was obtained in support of the 
involvement of all sinusoidal cells in TGF–β1 expression, in particular of stellate and 
endothelial cells (De Bleser et al., 1997). TGF–β1 plays a central role in the process of 
liver fibrosis, contributing to influx and activation of Kupffer cells as well as activation 
of HSC. TGF-β1 is produced by Kupffer cells and HSC, it up-regulates the transcription 
of collagen I and II genes and induces the expression of TIMP-1, a tissue inhibitor of 
MMP2 involved in collagen degradation (Bedossa & Paradis, 1995; Epstein et al., 
1994). Recently reported that the presence of the large TGF–β complex was 
conclusively demonstrated in rat liver stellate cells but also in parenchymal cells (Roth-
Eichhorn et al., 1998). Our result is in accordance with many reports mentioned that the 
fibrotic liver is characterised by an increased of TGF-β1. Supporting evidence were 
119 
 
obtained in rodent models of liver fibrosis (De Bleser et al., 1997; Parola et al., 1993; 
Pietrangelo et al., 1995; Poli & Parola, 1997). Furthermore, as reported by Leonarduzzi 
et al. (1997), such up-regulated TGF-β1 mRNA level led to a consistent and statistically 
significant rise of active TGF-β1 cytokine. Relevant to our finding, studies 
demonstrated that in rat fibrotic liver as induced by chronic treatment with CCl4 or by 
iron overload, suitable antioxidant treatment (vitamin E or sylibin) was significantly 
able to afford almost complete prevention of the marked up-regulation of hepatic 
TGFβ1 and collagen type I genes (Parola et al., 1992b; Pietrangelo et al., 1995). 
Moreover, extracellular degradation of matrix proteins is regulated by matrix 
metalloproteinase (MMPs) produced by HSC (Benyon & Arthur, 2001). In fact, level 
and activity of MMP are the result of a complex regulation of the expression of the 
coding genes, extracellular cleavage of pro-enzyme forms and specific inhibition by 
tissue inhibitors of metalloproteinase (TIMPs) (Arthur, 1998; Cawston, 1998). In case 
of liver injury, namely in its early stages, an increased expression of MMP has been 
reported, mainly dependent upon activation of stellate cells (Milani et al., 1994). On the 
other hand, a great bulk of evidence exists in support of an over-expression of TIMP-1 
and TIMP-2 in hepatic fibrosis (Arthur, 1998). Both TIMP-1 and TIMP-2 are released 
by fully activated stellate cells mainly through up-regulated transcription of the 
respective gene (Bahr et al., 1997; Roeb et al., 2005). Such increased expression of 
these two forms of MMP inhibitors is prominent in advanced liver fibrosis both in the 
experimental animal and in humans (Herbst et al., 1997). This hypothesis is supported 
by studies of experimental hepatic fibrosis and in human liver disease, in which TIMP-1 
expression is significantly up-regulated in cirrhotic liver compared with normal liver 
(Knittel et al., 2000). In consistent to our result, study by Clement et al. (1988) evidence 
has been obtained of mRNA expression for collagen types I in progressive liver fibrosis. 
Collagen type III is first increased after liver damage, later on largely substituted by 
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collagen type I. The amount of the latter type keeps increasing with the progression of 
the fibrotic process to sclerosis and cirrhosis, up to represent even 60-70 % of total 
collagen (Milani et al., 1990; Ramadori et al., 1998).  
 
5.5 Immunomodulatory Effects on PBMCs 
Many medicinal plants used in folk medicines have been shown to stimulate or suppress 
immune responses. Results from other studies have indicated non-specific immune-
stimulating or immune-modulating activities of a number of medicinal plants 
(Sriwanthana et al., 2007). Generally, any immune-stimulant agent has the ability to 
enhance the body’s defence against infections and cancer. Consequently these agents 
may be used as adjuncts to chemotherapy in immune-compromised patients such as 
cancer chemotherapy patients to alleviate infections, as well as to remove the residual 
cancer cells. It is well known that macrophages and other PMMCs play an important 
role in the defence mechanism against host infection and the killing tumour cells. The 
immunomodulatory activity of herbs and their active compounds is an area of research 
in cancer treatment (Kang et al., 2002). MTT assay was used for assaying PBMCs cell 
survival and proliferation. MTT is utilized by all living, metabolically active cells and 
the amount of MTT formazan generated is directly proportional to the cell number 
(Mosmann, 1983).  
Results of the present study have shown that both O. stamineus and M. citrifolia 
extracts at the serial concentration of 12.5 µg/ml to 200 µg/ml show promising PBMCs 
stimulating activities in a dose dependent manner. Furthermore 200 µg/ml treatments of 
both plant extracts significantly enhanced and increased the PMMCs cell viability, 
while 12.5, 25 and 50 µg/ml doses of both plants did not show significant changes as 
shown in (Figure 4.9). Our results suggested that the extracts of those plants have 
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stimulating activity on human PMMCs and could be useful to prevent the onset of 
cancer. O. stamineus contains high content of phenolic compounds and these 
compounds could affect the immune system due to the hydroxyl groups in their 
structure. The hydroxyl groups can stimulate the enzyme or electron-transferring 
system, thus resulting in immune-modulating properties, particularly in proliferation of 
macrophages and lymphocytes (Manosroi et al., 2003). Moreover, our results are in 
accordance with those reported by other authors in which the immunological activity of 
M. citrifolia fruit at various concentrations inhibited the production of tumour necrosis 
factor-alpha (TNF-α), which is an endogenous tumour promoter (Hirazumi et al., 1996). 
On the other hand, scopoletin is a phenolic compound isolated from M. citrifolia; was 
found induced cell proliferation of normal T-lymphocytes; this immunomodulatory 
effect was reported due to the interaction with kinase C (PKC) protein. These results 
indicate that scopoletin and some other phenolic and flavonoid compounds have 
immune-modulating activities (Manuele et al., 2006). 
 
5.6 In vitro hepatoprotective and antioxidant activities of plant crude extracts and 
isolated fractions 
H2O2 has been identified to have potential to generate free radicals in cell line and 
biological system. However, the cellular antioxidant enzymes SOD, CAT and GPx limit 
the effects of oxidant molecules on tissues and are active in the defence against 
oxidative cell injury by means of their being free radical scavengers (Kyle et al., 1987). 
These enzymes work together to eliminate active oxygen species and small deviations 
in physiological concentrations may have a dramatic effect on the resistance of cellular 
lipids, proteins and DNA to oxidative damage. The increased activities of antioxidant 
enzymes may be a compensatory regulatory response to increased oxidative stress. The 
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WRL-68 normal liver cell line was used, due to the fact that, although this cell line 
expresses some hepatic characteristics, it does not express alcohol dehydrogenase or 
cytochrome P450 activity, and the results could be considered as the toxic effect of 
thioacetamide and other chemicals induced liver cirrhosis in animals (Gutiérrez-Ruiz et 
al., 1994).  In addition, studies showed that chemicals can produce oxidative stress and 
hepatocyte toxicity on liver cells line. Moreover, all of these damage could be blocked 
by the administration of antioxidants (Bailey & Cunningham, 2002). In vitro 
experiments with human liver cells used for hepatoprotective evaluation have many 
potential advantages compared with conventional animal testing. One such advantage is 
that the cell line does not required large quantity of the examined compound as in 
animal experiment and this is useful for the evaluation of isolated compounds, which 
are usually in very small amount. The other advantage is the possibility of using human 
cellular models, thereby avoiding the difficulty of extrapolating animal data to humans 
(Olivares et al., 1997).  
The crude extracts and all isolated fractions were screened for their in vitro 
hepatoprotective activity against H2O2-induced liver cell line. Results indicate that both 
plant extracts and the two fractions; O. stamineus F3 and M. citrifolia F2 have the best 
ability to fight against H2O2 cell oxidative damage and enhanced the cell viability. The 
activity of O. stamineus and M. citrifolia crude extracts was found to be are in 
accordance with that of the in vivo evaluation, whereas better result obtained by O. 
stamineus F3 and M. citrifolia F2, in term of prevent the WRL-68 death and normalized 
the oxidative damage generated by H2O2 induction. Other fractions did not show highly 
significant difference when compared to H2O2 group. For the in vitro antioxidant 
studies, we noticed that O. stamineus F3 showed significant increase in cellular 
antioxidant enzymes; CAT and GPX compared to H2O2 group; at the same time 
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significantly reduced the MDA, which represent the lipid peroxidation. The crude 
extracts and M. citrifolia F2 have the same ability to induce the antioxidant enzymes but 
with less effect (Table 4.7). O. stamineus and M. citrifolia are rich in phenolic 
compounds and exhibits antioxidant capacity against oxidative stress, which in turn lead 
to increased cellular antioxidant enzymes. Nevertheless, SOD showed no significant 
difference between all groups and this may be explained by that the SOD has no action 
on H2O2 radicals, while CAT and GPx are the most abundant enzymes in the liver cell 
responsible for the catalytic decomposition of H2O2 to oxygen and water. SOD is an 
extremely effective antioxidant enzyme, but it is responsible for catalytic dismutation of 
superoxide radicals to H2O2 (Reiter et al., 2000).  
 
5.7 Phytochemicals investigation of the active fractions 
The LC-MS investigation of O. stamineus F3 showed the presence of ponkanetin, 
eupatorin, TMF (3-hydroxy-5, 7, 3, 4'-tetramethoxy flavone) and salvigenin, while M. 
citrifolia F2 showed the presence of scopoletin and p-coumaric acid compounds. The 
literature survey showed that compounds such as eupatorin  and 3'- hydroxyl-5, 7, 3, 4'-
tetramethoxy flavone were previously isolated from O. stamineus (Akowuah et al., 
2005a; Olah et al., 2003; Tezuka et al., 2000). On the other hand, a number of studies 
have identified many phenolic compounds in M. citrifolia including scopoletin and P-
coumaric acid (Jayaraman et al., 2008; Levand & Larson, 1979; Wang et al., 2002).  
The therapeutic effects of O. stamineus have been referred mainly to its polyphenols, 
which are the most dominant constituents in the leaf that has been reported by Hollman 
& Katan (1999) to be effective in reducing oxidative stress by inhibiting the formation 
of lipid peroxidation products in biological systems which could lead to some of the 
chronic diseases such as coronary heart disease and cancer. The leaves were reported to 
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have the highest antioxidant properties whereby the phenolic fraction is the most active 
principle among the phytochemicals studied (Pietta et al., 1998), so the leaves of this 
herb are often used in traditional medicine compared to other parts of the plant. 
According to Sumaryono et al. (1991), the derivatives of caffeic acid, were reported to 
constitute 67 % of total identified phenolics in methanol extract and about 94.6 % in hot 
water extract. 
Recent findings showed that the flavonoid compounds; ponkanetin, eupatorin, 
tetramethoxy flavone and salvigenin, as well as scopoletin and P-coumaric acid were 
also effective as antioxidant, free radical scavenging, anticancer, anti-proliferative,  anti-
fibrotic and hepatoprotective agents (Akowuah et al., 2004; Androutsopoulos et al., 
2008; Nagao et al., 2002; Okafor & Dioka, 2011; Ponce et al., 2004; Rafatian et al., 
2012; Tezuka et al., 2000; Yam et al., 2009; Zang et al., 2000). Thus, the plant-derived 
antioxidants represent valuable anti-fibrotic drugs. 
 
5.8 Antibacterial activity 
The antibacterial assay showed that both aqueous and ethanol extracts of O. stamineus 
exhibited activity against Gram-positive bacteria (Staphylococcus aureus and 
Streptococcus agalactiae) but not against Gram-negative bacteria (Escherichia coli and 
Klebsilla pneumonia). Among the investigated extracts, the aqueous extract of O. 
stamineus showed the best antibacterial efficacy against Staphylococcus aureus and 
Streptococcus agalactiae, while M. citrifolia did not show any antibacterial activity 
(Table 4.10). 
In general, plants are rich in a wide variety of chemical compounds, such as alkaloids, 
tannins, flavonoids and terpenoids, with antimicrobial activities (Cowan, 1999). The 
reported antibacterial activities of O. stamineus extracts were related to their high 
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content of rosmarinic acid (Ho et al., 2010; Huang & Zheng, 2006). The results of this 
study are in agreement with the results published by Ho et al. (2010) who reported the 
antimicrobial activities of methanol extracts of the O. stamineus against selected food-
borne bacteria. Moreover, O. stamineus showed markedly inhibition of the growth of 
Vibrio parahaemolyticus and Streptococcus mutans. It was claimed that saponins and 
caffeic acid derivatives could be responsible for the antimicrobial activity of this herb 
(Ho et al., 2010).  
 
5.9 Conclusion  
In conclusion, this study showed that the ethanol extracts of O. stamineus and M. 
citrifolia have hepatoprotective effects and antioxidant properties that were proven in 
vivo against thioacetamide-induced liver cirrhosis in rats and in vitro against WRL-68 
normal liver cell line. In addition, the active constituents identified in both plants have 
confirmed and correlate to the antioxidant and hepatoprotective activity. Furthermore, 
this study revealed that the high dose 200 mg/kg of O. stamineus exerted a significant 
hepatoprotective and antioxidant effect as proven by biochemical, antioxidant and 
histopathological analysis. Accordingly, O. stamineus could be an effective herbal and 
efficient remedy for chemical-induced hepatic cirrhosis. Consequently, this activity 
could be claimed to the following identified flavonoids compounds; ponkanetin, 
eupatorin, TMF and salvigenin as confirmed by the in vitro assays. On the other hand, 
the high dose 200 mg/kg of M. citrifolia exhibited antioxidant and hepatoprotective 
activity but less than that of O. stamineus and this activity may be attributed to the 
presence of scopoletin and P-coumaric acid. O. stamineus treatment resulted in 
significant increase in the levels of total antioxidants, reduced oxidative stress and 
enhanced the activities of antioxidant enzymes (SOD, CAT and GPx) suggesting that 
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the reduction of oxidative stress likely plays a role in the mechanism of its 
hepatoprotective effects. The other possible mechanism of hepatoprotective and liver 
regeneration action of both plant extracts could be due to the free radical scavenging, 
antioxidant properties, high phenolic and flavonoid contents and anti-lipid peroxidation 
activities, furthermore may be as consequence of a significant down-regulation of the 
liver fibrosis involved genes expression; namely; TGFβ1, MMP2 and Coll α genes, in 
contrast to the over-expression of those three genes in liver cirrhosis. 
The obtained results indicate that O. stamineus exhibits potent antioxidant activity and 
stimulating activity on human PBMCs which might be useful for therapeutic purposes 
to prevent ROS disorders and enhance the immune system, and could be used as a 
potential immunomodulatory agent for tumor immunotherapy. Moreover O. stamineus 
has some interesting antibacterial efficacy, especially against Gram positive bacteria. 
These findings indicate that O. stamineus showed high antioxidant, antibacterial and 
immune-modulating activity and may be considered as an immunomodulatory and 
antibacterial agent. 
 
In summary, the results of our study indicate that O. stamineus and M. citrifolia are safe 
and effective alternative chemo-preventive. Thus, they could be promising candidate 
drugs that merits further preclinical development and pharmacological studies with a 
view to determining its eventual suppressive and therapeutic potential. Furthermore, our 
results offer a scientific basis for the traditional use of these medicinal plants. 
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5.10 Future work  
Further studies need to confirm the potential of active constituents isolated from these 
plant extracts such as the bioavailability, pharmacodynamics, pharmacokinetics and 
other pharmacological evaluations. In addition, the amount of the antioxidant should be 
compared to what actually biologically available in the blood after the plant extract 
administration. Moreover, study the mechanism of action for the prevention of the 
oxidative stress applied on cell line such as apoptosis and necrosis using flow cytometry 
method.  
Finally, future studies to be undertaken in relation with these results to screen the 
medicinal plants that are used in traditional medicine to prevent the liver diseases, 
should be done for screening of potential active constituents. 
 
 
.  
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APPENDIXES 
APPENDIX I Forms and photos  
A. Acute toxicity ethic approval   
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B. LC/MC analysis request form (CARIF) 
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C. Some photos of different steps in the in vivo hepatoprotective an animal model 
experiment  
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APENDIX II Reagents preparation and laboratory protocols 
 
A. Phosphate buffer saline (PBS) 
A total of 10 Tablet of phosphate buffer saline (Sigma-Aldrich, UK) were added to 
1000 ml of distilled water (as described by manufacture) and mixed well. The pH was 
adjusted between 7-7.4 if necessary and the solution was autoclaved at 120
o
C for 15 
min. 
 
B. 10 % buffered formalin solution 
To make a solution of 10% Formalin, nine parts of water were added to one part of 40% 
(aqueous) Formaldehyde and the pH was adjusted between 7-7.4 by adding PBS Tablet 
and mixed gently. Therefore, to prepare 1000 ml: 
Formaldehyde (37-40%) -------------------100 ml 
Distilled water ---------------------------    900 ml 
PBS Tablet (Sigma-Aldrich, UK) ----------10 Tablets 
 
Mix to dissolve. 
 
C. Tissue processing (automated machine procedures) 
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D. Hematoxylin-eosin (H&E) staining protocol 
 
Basic steps of staining: 
 
-  De-waxing with xylene 
- Re-hydration 
- Staining 
- Dehydration with xylene 
- Mounting 
 
To bring section to water (de-wax and re-hydrate) before staining: 
- Place slide in xylene    3 minutes x2 
- Drain off excess xylane 
- Transfer slide to absolute alcohol  2 minutes x1 
- Transfer slide to 95 % alcohol   2 minutes x2 
- Transfer slide to 70 % alcohol   2 minutes x1 
- Leave in slow running tap water  3 minutes 
- Section now is ready for staining 
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E. 2 % denaturing agarose gel electrophoresis and ethidium bromide staining 
 
To prepare agarose gel (2 % agarose), mix: 
2 gm of agarose 
100 ml 1x TEA (Tris-acetate-EDTA) buffer (2 ml 10x TEA buffer + 98 ml nuclease-
free water) 
If smaller or larger gels are needed, adjust the quantities of components proportionately. 
Heats the mixture in microwave to melt agarose until become dissolve completely. Cool 
to 65°C in a water bath. Add 1 μl of a 10 mg/ml ethidium bromide stock solution. 
Mix thoroughly and pour onto gel support. Before running the gel, equilibrate in 1x 
TEA gel running buffer for at least 30 minutes. 
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APENDIX III Manufacturer kits instruction and procedures 
A. Antioxidant Cayman assay 
1. Antioxidant assay kit (Item No. 709001 Cayman) 
154 
 
 
155 
 
2. Catalase assay kit (Item No. 707002 Cayman) 
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3. Superoxide dismutase assay kit (Item No. 706002 Cayman) 
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4. Glutathione peroxidase assay kit (Item No. 703102 Cayman) 
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5. TBARS (MDA) assay kit (Item No. 10009055 Cayman) 
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B. Gene expression kits 
1. QIAamp® RNA Blood Mini Handbook, for total RNA purification  
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2. High Capacity RNA-to-cDNA Master Mix Kit (Reverse Transcription) 
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3. TaqMan® Fast Advanced Master Mix Protocol 
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4. TaqMan® Gene Expression Assay protocol  
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C. Histopaque-1077 kit 
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D. WRL-68 (ATCC Catalog) 
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APENDIX IV Raw data and result 
A. Blood analysis result form (Central Diagnostic Laboratory, University of 
Malaya Medical Centre)   
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B. DPPH, FRAP and ABTS standard curves 
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C. RNA concentration and purity measured by NanoDrop 2000 
spectrophotometer  
 
Sample  
Conc. 
ng/µl 
260/280 260/230 A 230 A 260 A 280 A 320 
Calibrator 1 647 1.974 2.052 0.788 1.618 0.820 0.005 
Calibrator 2 329 2.013 2.075 0.396 0.882 0.409 0.003 
Calibrator 3 503 2.000 2.054 0.612 1.257 0.628 0.006 
Calibrator 4 464 1.997 2.125 0.545 1.159 0.580 0.004 
Calibrator 5 641 1.974 1.781 0.900 1.602 0.812 0.005 
Calibrator 6 516 2.003 2.056 0.637 1.290 0.644 0.004 
Calibrator 7 879 1.776 1.867 1.177 2.197 1.237 0.007 
TAA 1 225 2.017 1.777 0.409 0.563 0.279 0.002 
TAA 2 577 1.991 1.949 0.740 1.443 0.725 0.005 
TAA 3 281 2.020 1.685 0.494 0.703 0.348 0.003 
TAA 4 522 2.009 1.683 0.776 1.305 0.650 0.005 
TAA 5 884 1.836 1.880 1.236 2.211 1.300 0.007 
TAA 6 724 1.950 1.952 0.927 1.809 0.928 0.005 
TAA 7 284 2.017 2.039 0.348 0.710 0.352 0.002 
O. stamineus 1 76.9 2.031 1.864 0.222 0.192 0.095 0.000 
O. stamineus 2 130 2.012 1.302 0.249 0.324 0.161 0.001 
O. stamineus 3 276 2.032 1.750 0.600 0.690 0.340 0.002 
O. stamineus 4 279 2.034 1.783 0.590 0.699 0.343 0.002 
O. stamineus 5 482 2.016 1.946 0.619 1.204 0.597 0.005 
O. stamineus 6 364 2.022 1.698 0.537 0.911 0.451 0.003 
O. stamineus 7 248 2.016 1.948 0.318 0.620 0.307 0.002 
M. citrifolia 1 554 1.990 2.105 0.658 1.384 0.696 0.006 
M. citrifolia 2 551 1.993 2.122 0.649 1.377 0.691 0.005 
M. citrifolia 3 556 1.999 1.834 0.758 1.390 0.696 0.004 
M. citrifolia 4 575 1.984 2.103 0.684 1.438 0.725 0.004 
M. citrifolia 5 316 2.012 1.715 0.489 0.789 0.392 0.003 
M. citrifolia 6 629 1.988 1.754 0.897 1.573 0.791 0.005 
M. citrifolia 7 541 1.999 1.984 0.682 1.353 0.677 0.004 
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D. Expression stability of four endogenous reference genes using NormFinder and 
geNorm algorithm  
 
1. NormFinder analysis: 
 
 
Gene Name SD SD 0.4304 
HPRT1 0.4304     
GPDH 0.5031 Best Gene HPRT1 
Ppia 0.5706     
Actin β 1.28     
 
Output  summary  
Best Genes:  HPRT 1  
SD : 0.4304 (lowest variability) 
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2. geNorm analysis: 
 
 
Gene Name M-Value 
Actin β 1.02737671033742 
GPDH 0.7103238761604 
HPRT1 0.631837272682082 
Ppia 0.631837272682082 
 
Output  summary  
Best Genes combination: Ppia and HPRT-1  
M value: 0.6318 (stable expression) 
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E.  Standard Curve and efficiency for target and endogenous reference genes  
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